WO1989005849A1 - Lactic acid bacteria for use in fermented milk products and veterinary compositions - Google Patents
Lactic acid bacteria for use in fermented milk products and veterinary compositions Download PDFInfo
- Publication number
- WO1989005849A1 WO1989005849A1 PCT/DK1988/000222 DK8800222W WO8905849A1 WO 1989005849 A1 WO1989005849 A1 WO 1989005849A1 DK 8800222 W DK8800222 W DK 8800222W WO 8905849 A1 WO8905849 A1 WO 8905849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- pigs
- bacteria
- composition
- powder
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 156
- 241000894006 Bacteria Species 0.000 title claims abstract description 134
- 239000004310 lactic acid Substances 0.000 title claims abstract description 78
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 235000014048 cultured milk product Nutrition 0.000 title claims abstract description 26
- 241000282887 Suidae Species 0.000 claims abstract description 68
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 30
- 230000002496 gastric effect Effects 0.000 claims abstract description 20
- 210000000941 bile Anatomy 0.000 claims abstract description 18
- 210000000981 epithelium Anatomy 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 21
- 241000186660 Lactobacillus Species 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000002609 medium Substances 0.000 claims description 18
- 230000020477 pH reduction Effects 0.000 claims description 16
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 15
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 15
- 230000001332 colony forming effect Effects 0.000 claims description 15
- 239000012298 atmosphere Substances 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 210000002919 epithelial cell Anatomy 0.000 claims description 14
- 239000006872 mrs medium Substances 0.000 claims description 14
- 210000002784 stomach Anatomy 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 13
- 229940039696 lactobacillus Drugs 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 13
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 10
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 9
- 206010017964 Gastrointestinal infection Diseases 0.000 claims description 9
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002953 phosphate buffered saline Substances 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 230000000369 enteropathogenic effect Effects 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 210000001630 jejunum Anatomy 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- -1 drench Substances 0.000 claims description 5
- 239000003651 drinking water Substances 0.000 claims description 5
- 235000020188 drinking water Nutrition 0.000 claims description 5
- 239000008151 electrolyte solution Substances 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 210000000813 small intestine Anatomy 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 210000003405 ileum Anatomy 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 6
- 241000282898 Sus scrofa Species 0.000 description 31
- 230000000694 effects Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 210000000936 intestine Anatomy 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 15
- 244000052769 pathogen Species 0.000 description 15
- 239000006041 probiotic Substances 0.000 description 13
- 230000000529 probiotic effect Effects 0.000 description 13
- 235000018291 probiotics Nutrition 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000003674 animal food additive Substances 0.000 description 7
- 244000144980 herd Species 0.000 description 7
- 229960001031 glucose Drugs 0.000 description 6
- 244000005706 microflora Species 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 235000010633 broth Nutrition 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229930182843 D-Lactic acid Natural products 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940022769 d- lactic acid Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 210000004085 squamous epithelial cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 2
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 2
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004187 Spiramycin Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000004188 Virginiamycin Substances 0.000 description 2
- 108010080702 Virginiamycin Proteins 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940089837 amygdalin Drugs 0.000 description 2
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 2
- 108010053278 avoparcin Proteins 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229960000427 carbadox Drugs 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BPMVRAQIQQEBLN-OBPBNMOMSA-N methyl n-[(e)-(1-hydroxy-4-oxidoquinoxalin-4-ium-2-ylidene)methyl]iminocarbamate Chemical compound C1=CC=C2N(O)C(=C/N=NC(=O)OC)/C=[N+]([O-])C2=C1 BPMVRAQIQQEBLN-OBPBNMOMSA-N 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 239000010499 rapseed oil Substances 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019372 spiramycin Nutrition 0.000 description 2
- 229960001294 spiramycin Drugs 0.000 description 2
- 229930191512 spiramycin Natural products 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 235000019373 virginiamycin Nutrition 0.000 description 2
- 229960003842 virginiamycin Drugs 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NNDHDYDFEDRMGH-CAEIVAEBSA-N Anthranoyllycoctonine Chemical compound C([C@]12CN(C3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N NNDHDYDFEDRMGH-CAEIVAEBSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004184 Avoparcin Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 101100352919 Caenorhabditis elegans ppm-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- QWIZNVHXZXRPDR-KMHATNSDSA-N D(+)-Melezitose Chemical compound OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O QWIZNVHXZXRPDR-KMHATNSDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108010001539 D-lactate dehydrogenase Proteins 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004181 Flavomycin Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UXOXDDUEWZOAIW-UHFFFAOYSA-N Inuline Natural products CCN1CC2(CC(=O)Oc3ccccc3N)CCC(OC)C45C6CC7C(CC(O)(C6C7OC)C(O)(C(OC)C24)C15)OC UXOXDDUEWZOAIW-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- XQCFHQBGMWUEMY-ZPUQHVIOSA-N Nitrovin Chemical compound C=1C=C([N+]([O-])=O)OC=1\C=C\C(=NNC(=N)N)\C=C\C1=CC=C([N+]([O-])=O)O1 XQCFHQBGMWUEMY-ZPUQHVIOSA-N 0.000 description 1
- TURHTASYUMWZCC-UHFFFAOYSA-N Olaquindox [BAN:INN] Chemical compound C1=CC=C2N([O-])C(C)=C(C(=O)NCCO)[N+](=O)C2=C1 TURHTASYUMWZCC-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 241001351225 Sergey Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- VNRZCPPHNPEBFC-UHFFFAOYSA-N anthranoyllycoctonine Natural products CCN1CC2(COC(=O)c3ccccc3N)CCC(OC)C45C2C(OC)C(O)(C14)C6(O)CC(OC)C7CC5(O)C6C7OC VNRZCPPHNPEBFC-UHFFFAOYSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000021052 average daily weight gain Nutrition 0.000 description 1
- 235000019377 avoparcin Nutrition 0.000 description 1
- JWFVWARSGMYXRN-HTQQBIQNSA-N avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 description 1
- 229950001335 avoparcin Drugs 0.000 description 1
- OTKPPUXRIADSGD-PPRNARJGSA-N avoparcina Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2C([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C(C=C2)[C@@H](O)[C@H](C(N[C@H](C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@H]1C[C@@H](N)[C@@H](O)[C@H](C)O1 OTKPPUXRIADSGD-PPRNARJGSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- PERZMHJGZKHNGU-JGYWJTCASA-N bambermycin Chemical compound O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(C)=O)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@H](O1)C(=O)NC=1C(CCC=1O)=O)O)C)[C@H]1[C@@H](OP(O)(=O)OC[C@@H](OC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)C(O)=O)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]1OC(N)=O PERZMHJGZKHNGU-JGYWJTCASA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SRBFZHDQGSBBOR-KLVWXMOXSA-N beta-L-arabinopyranose Chemical compound O[C@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KLVWXMOXSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019374 flavomycin Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- SUSRLLXAXAIZPH-OBPIAQAESA-N hydroquinone beta-D-glucopyranoside Natural products OC[C@H]1O[C@@H](Cc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O SUSRLLXAXAIZPH-OBPIAQAESA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 101150026107 ldh1 gene Proteins 0.000 description 1
- 101150041530 ldha gene Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229950010210 olaquindox Drugs 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940088336 primor Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/179—Sakei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present invention relates to lactic acid bacteria isolated from the gastrointestinal tract of pigs and a fermented milk product comprising such bacteria, as well as to a powder and a veterinary Composition comprising the bacterium and the use thereof in the. prophylaxis or treatment of pig gastrointestinal diseases.
- Fermented milk products have long been known to be a beneficial component of human diet as they combine the nutritive value of milk in terms of protein content, including a favourable amino acid composition, content of fat and overall energy content (slightly less than in unfermented milk due to the conversion of lactose to lactic acid through the action of lactic acid bacteria) and the increased digestibility established for fermented milk products (Livia Aim, "The Effect of Fermentation on Nutrient in Milk and some Properties of Fermented Liquid Milk Products", Naringsforskning 27 , 1983, pp. 2-8).
- the improved digestibility is obtained by precipitation of the milk protein (casein) into fine curd particles which are more easily digested by the enzymes present in the digestive tract than the large casein particles resulting from the action of gastric juice on unfermented milk. Furthermore, the fermentation process causes a significant hydrolysis of the proteins present in the milk into smaller peptides and free amino acids, and this so-called pre-digestion of the proteins makes it easier to degrade them by the digestive enzymes. Lactic acid fermentation also tends to favourably affect the utilization of calcium in the body in the form of calcium lactate which is more easily absorbed in the body.
- the lactic acid bacteria present In the fermented milk may inhibit the growth of pathogenic or potentially pathogenic microorganisms in the intestinal tract by producing various organic acids (primarily lactic acid and, to a smaller extent, acetic, propionic and formic acid) which lower the intestinal pH so as to inhibit acid-sensitive organisms.
- Some lactic acid bacteria also produce antimicrobial substances known as biocines which contribute to controlling the growth of pathogens in the intestines.
- a high concentration of lactic acid bacteria in the intestines may also be employed prophylactically to protect against attacks from pathogenic bacteria.
- Ingestion of fermented milk products may therefore be advantageous in order to maintain a good biological balance of the intestinal flora of a healthy person and possibly also to redress the imbalance in the intestinal flora occasioned by various conditions such as intestinal diseases and disorders (e.g. diarrhoea), functional disorders of the digestive tract, or the after-effects of antibiotic treatment and radiation therapy.
- intestinal diseases and disorders e.g. diarrhoea
- functional disorders of the digestive tract e.g. diarrhoea
- Fermented milk products comprising lactic acid bacteria and alleged to exert a beneficial effect by maintaining the normal balance of the intestinal flora are commercially available and are described by, for instance, Frank V. Kosikowski in Cheese and Fermented Milk Foods , 2nd Ed., 1978, pp. 37-48. To the present inventors' best knowledge, however, the ability of the bacteria used in these products to survive in a gastrointestinal environment has not been adequately documented.
- One object of the present invention Is therefore to provide lactic acid bacteria which show advantageous properties with respect to survival in the gastrointestinal tract when included in a fermented milk product intended for human consumption.
- Another object of the present invention is to provide lactic acid bacteria with useful properties for the prophylaxis or treatment of pig gastrointestinal diseases. Gastrointestinal infections frequently occur in pigs, especially young pigs, resulting in retardation of the growth rate and even death of some of the infected pigs.
- Enteric diseases in pigs may be of bacterial, viral or protozoal origin and are, in the case of bacteria, initiated by a colonization of the gastrointestinal epithelium with pathogenic organisms which compete with the normal intestinal flora and, if successfully established, produce (depending on the species) exotoxins (enterotoxins) which in sufficient quantities, that is when the organism producing them has ousted the normal bacterial flora from the intestines, produce a variety of disease symptoms in the host, notably diarrhoea leading to an occasionally fatal loss of fluid from tissues and in a decreased feed consumption as well as utilization of the feed.
- Enteropathogenic organisms are easily transmitted from one pig to another through their presence in the faeces of infected animals present in their environment, and therefore the disease may very quickly be transmitted from the initially infected animal to the rest of the herd.
- gastrointestinal infections present a major source of economic loss to pig breeders.
- Gastrointestinal diseases in pigs have usually been combated with antibiotics.
- antibiotics have been administered prophylactically to neonatal pigs or to gestating sows before farrowing.
- this procedure suffers from the disadvantage that it eliminates the natural intestinal flora, making the animals more vulnerable to invasion by opportunistic pathogens which colonize the intestines more rapidly than the natural microflora. This may, in turn, give rise to bacterial infection after the antibiotic treatment has ceased.
- Another frequent result of antibiotic treatment is the development of antibiotic-resistant strains of the pathogens.
- US 3,953,609 discloses a method of changing the digestive system bacteria in animal by orally feeding the animals live Lactobacillus lactis NRRL B-5628 in an amount of 1 ⁇ 10 10 cells/kg body weight/day to reduce the number of other gastrointestinal tract bacteria.
- the purpose is to provide prophylaxis or treatment of colibacillosis in animals such as swine, cattle and poultry.
- the bacterial strain was isolated from human faeces.
- US 4,314,995 discloses a method of treating infections by local administration of the Lactobacillus strains FRI 1946, 2779, 2780, 2781 or 2782, optionally together with an antibiotic.
- diseases suggested for treatment in the patent by means of these bacteria are gastritis and enteritis for which applications the bacteria are preferably administered together with antibiotics.
- the bacteria are stated to be bile resistant, but their origin is not indicated. The bacteria appear to be intended for use in humans only.
- EP 203 586 discloses the use of Lactobacillus fermentum ATCC 53113 or mutants thereof for treating gastrointestinal diseases in domestic animals such as pigs, cows, sheep, goats and horses. The strain is indicated to have been isolated from the gut of a healthy newborn Pig. SUMMARY OF THE INVENTION he present inventors have now isolated probiotic lactic acid bacteia from the digestive tract of pigs which bacteria have been careully selected for properties which are useful when the organisms re to be employed in fermented milk products for the prophylaxis or reatment of pig gastrointestinal infections. ccordingly, the present invention relates to a lactic acid bacterium hich is viable in the gastrointestinal tract of human beings and igs, the bacterium being isolated from the gastrointestinal tract of pig and selected according to the following criteria:
- iv defined as the production of at least 10 g/l of lactic acid (D- and L-forms) when grown in MRS medium, pH 6.2, for up to 48 hours at 37°C in an atmosphere containing 10% CO 2 in
- probiotic is used to indicate cultures of non-pathogenic gastrointestinal bacteria or compositions containing such cultures which, after the ingestlon of effective doses, may survive or even become established in the gastrointestinal tract and thereby preserve or enforce the function of the microflora as a barrier against the colonization of the epithelium by pathogenic organisms.
- the bacteria of the invention are capable of surviving the conditions prevailing in the gastrointestinal tract.
- the criteria according to which the bacteria of the invention have been selected have primarily been employed to achieve this overall effect.
- the lactic acid bacteria of the invention have been systematically screened for their viability under gastrointestinal conditions in pigs.
- the bacteria of the invention Due to the well-known similarities between the human and porcine digestive systems, the fact that the bacteria of the invention have been shown to establish themselves in the intestines of pigs renders probable their ability to survive in the human gastrointestinal tract as well.
- survival of the bacteria in the digestive tract is the most important selection criterion as regular ingestion of a fermented milk product containing the bacteria will usually be sufficient to ensure a sufficient number of the bacteria in the intestines to provide a favourable regulation of the intestinal flora.
- the bacteria of the invention are intended to be used therapeutically, however, it has been found to be advantageous that they show good adhesion properties since this improves their ability to colonize the gastrointestinal mucosa and compete successfully with the pathogens or potential pathogens present in the intestines, thus obtaining a favourable balance of the gastrointestinal microflora.
- the adhering bacteria form a layer on the epithelium and prevent access of the pathogens to the receptors present on the epithelial cells.
- the bacteria preferably adhere to pig gastrointestinal tissue in a number of at least 4, preferably at least 16, most preferably at least 50, per epithelial cell.
- lactic acid is another important selection criterion since most pathogens show a significantly decreased growth rate in the presence of acid.
- Bile and acid tolerance are also essential for a probiotic bacterium to be employed successfully in the intestines, in particular the upper small intestines in order to be able to survive passage of the stomach and Intestines, and possibly to colonize the epithelium In the vicinity of the biliary tract. Since most pathogens tend to multlply very quickly, It is also essential that the lactic acid bacteria employed as the probiotic organisms have a brief generation time so that they may compete with the pathogens in the intestines.
- Certain lactic acid bacteria have been found to produce one or more antimicrobial agents such as hydrogen peroxide. Such substances are known to possess an inhibitory effect on a variety of microorganisms and therefore supplement the effect of pH decrease ascribable to the production of lactic acid.
- Mutants of the bacteria may either occur spontaneously (as is often the case in nature) or be produced deliberately such as by treatment with a chemical mutagen such as mitomycin C, 5-bromouracil, methylmethane sulphonate, nitrogen mustard and the nitrofurans, ionizing radiation, ultraviolet radiation, or by applying recombinant DNA techniques.
- a chemical mutagen such as mitomycin C, 5-bromouracil, methylmethane sulphonate, nitrogen mustard and the nitrofurans, ionizing radiation, ultraviolet radiation, or by applying recombinant DNA techniques.
- the term “functionally equivalent” should be taken to mean a mutant which shows similar properties to the parent strain with respect to establishing itself and competing with the pathogens present in the intestines at the time the bacteria are administered or entering the Intestines at some later point.
- Ingestion of a fermented milk product containing lactic acid bacteria of the invention for the purpose of regulating digestive functions or prophylactic or therapeutic administration of a lactic acid bacterium of the invention promotes the establishment of the normal, healthy microflora in the Intestines thereby creating or recreating a balanced intestinal environment where enteropathogens have difficulties in establishing themselves.
- it may, in case of actual gastrointestinal infections, furthermore be advantageous to administer the lactic acid bacteria concomitantly with or subsequently to antibiotic treatment in order to restore a healthy balance of the intestinal flora.
- antibiotic treatment of pig gastrointestinal tract infections be dispensed with altogether and replaced by administration of the lactic acid bacteria of the invention.
- Probiotic bacteria useful for the present purpose may, in principle, be any lactic acid bacteria isolated from porcine gastrointestinal epithelium, preferably the epithelium of healthy pigs. Suitable strains may be selected after isolation by screening procedures comprising testing for adhesive properties, production of lactic acid, acid and bile tolerance and generation time as described in further detail in Examples 1-5 and 8 below.
- the bacteria may be isolated from pigs of varying ages so as to ensure the availability of strains which are able to colonize the epithelium at different stages of the pigs' lives.
- Specific examples of lactic acid bacterial strains which may be employed in the present invention include strains selected from the genus Lactobacillus , e.g. L.
- the two Lactobacillus salivarius strains indicated above have been found to be particularly suitable as they not only provide the beneficial effects described above, but also result in an agreeable taste of the product.
- the bacteria may be propagated by growing the selected strain or strains in a suitable culture medium under anaerobic conditions for a period of time sufficient to provide at least 10 6 viable bacteria/ml of medium and harvesting the resulting bacteria from the medium.
- the cultivation temperature will typically be about 37°C, and the pH in the range of about 5.5-6.5.
- the present invention relates to a liquid or frozen concentrate comprising lactic acid bacteria of the invention.
- a liquid or frozen concentrate comprising lactic acid bacteria of the invention.
- the concentrate may be prepared by, for instance, centrifugation or filtration.
- the concentrate may suitably comprise 1 ⁇ 10 4 -1 ⁇ 10 12 viable colony-forming units/ml.
- the concentrate may contain a mixture of two or more of the Lactobacillus strains indicated above.
- the present invention relates to a freeze-dried or spray-dried powder comprising a lactic acid bacterium as described above.
- a freeze-dried or spray-dried powder comprising a lactic acid bacterium as described above.
- a stabilising or cryoprotective agent to the concentrate before drying as for instance disclosed in US 3,897,307.
- the resulting dried powder preferably comprises 10 4 -10 12 viable colony-forming units/g. It may be an advantage that the powder comprises a mixture of two or more lactic acid strains such as those listed above, in order to secure a broad-spectrum activity of the powder when used as or in a preparation to be administered to pigs of varying ages.
- the invention relates to a fermented milk product which comprises a lactic acid bacterium of the present invention.
- the product Is primarily intended for human consumption, and although it is primarily ingested for its nutritive value, it may be particularly useful for dietary purposes, i.e. for its favourable influence on digestive properties ascribable to the ability of the lactic acid bacteria to inhibit the growth of pathogenic or potentially pathogenic microorganisms.
- the fermented milk product of the invention may contain a mixture of two or more of the Lactobacillus strains listed above, and preferably also contains a Bifidobacterium sp. such as B . bifidum or B . longum, as well as L . acidophilus .
- the fermented milk product may be prepared by inoculating milk with a culture of the bacterium of the invention in a manner known per se , e.g. as described by A.Y. Tamine and R.K. Robinson in Yoghurt Science and Technology, 1985, preferably in the form of the liquid or frozen concentrate or freeze-dried or spray-dried powder described above. Consequently, the present invention also relates to the use of the lactic acid bacterium or a liquid or frozen concentrate or freeze- dried or spray-dried powder containing it for the production of a fermented milk product.
- the inoculation level is typically in the range of 1 ⁇ 10 5 -1 ⁇ 10 8 bacteria/ml of milk, such as 5 ⁇ 10 6 bacteria/ml.
- the lactic acid bacteria of the invention have been found capable of reducing the occurrence and/or severity of gastrointestinal tract infections in pigs caused by enteropathogenic microorganisms.
- the term "reducing the occurrence” is understood to mean that there are fewer cases of gastrointestinal infections both among individual pigs within each herd and among herds on the same farm, relative to pigs which have not been treated with the lactic acid bacteria of the invention.
- the gastrointestinal tract infections which may be prevented or treated by administering the bacteria of the invention may be any infections resulting from the presence and multiplication of enteropathogenie microorganisms in the Intestines, e.g. diarrhoeas, scours, etc. Examples of enteropathogens are E. coli and rotavirus.
- the present invention relates to a veterinary composition for the prophylaxis or treatment of gastrointestinal tract infections in pigs caused by enteropathogenie microorganisms, the composition comprising a lactic acid bacterium as described above and an excipient or carrier.
- the composition should preferably comprise 10 3 -10 12 viable colony-forming units/g since in this range a sufficient number of bacteria will normally survive the passage of the pigs stomach to colonize the intestinal epithelium in sufficient numbers to compete successfully with the pathogens or other microorganisms present.
- the composition may be formulated according to conventional veterinary practice as a powder, granulate, tablet, capsule, paste, gel, drench, mixture or suspension.
- Solid formulations i.e. powders, granulates, tablets and capsules, may contains fillers, e.g. sugars, sorbitol, mannitol and silicic acid; binders, e.g. cellulose derivatives such as carboxymethyl cellulose and polyvinylpyrrolidone; disintegrants, e.g. starch, sodium bicarbonate and calcium carbonate; lubricants, e.g. magnesium stearate, talc and calcium stearate.
- fillers e.g. sugars, sorbitol, mannitol and silicic acid
- binders e.g. cellulose derivatives such as carboxymethyl cellulose and polyvinylpyrrolidone
- disintegrants e.g. starch, sodium bicarbonate and calcium carbonate
- Semi-solid formulations i.e. pastes or gels, may comprise a gelling agent such as an alginate, gelatin, carrageenan, tragacanth gum and pectin, a mineral oil such as liquid paraffin, a vegetable oil such as corn oil, sunflower oil, rape oil and grape kernel oil, as well as a thickener such as a starch, gum, gelatin, etc.
- a gelling agent such as an alginate, gelatin, carrageenan, tragacanth gum and pectin
- a mineral oil such as liquid paraffin
- a vegetable oil such as corn oil, sunflower oil, rape oil and grape kernel oil
- a thickener such as a starch, gum, gelatin, etc.
- Liquid formulations i.e. drenches, mixtures and suspensions, may comprise a liquid or oily vehicle, e.g.
- Oily vehicles comprise a mineral oil such as liquid paraffin, a vegetable oil such as corn oil, sunflower oil, rape oil, grape kernel oil, etc.
- the freeze-dried or spray-dried powder of the invention may be suspended in the liquid vehicle in accordance with usual practice.
- the powder formulation may advantageously be the freeze-dried or spray-dried powder described above, either in itself or formulated with one or more further excipients.
- the solid formulations may be provided with a coating to protect the bacteria from gastric conditions so that they will more easily survive the passage of the stomach.
- the coating should be one which is degradable in a gastrointestinal environment.
- the coating is preferably one which is soluble in the stomach (though only gradually so that the protective effect will be maintained) or in the upper part of the small intestines. Examples of suitable coatings are alginates or lipids.
- composition of the invention may also comprise a mixture of two or more lactic acid bacterial strains such as the strains listed above.
- the composition may further comprise other active agents such as antibiotics, chemical growth promoters, or microorganisms or enzymes which have a growth promoting effect.
- the present invention relates to the use of a lactic acid bacterium as defined above for preparing a veterinary composition for the prophylaxis or treatment of gastrointestinal tract infections in pigs caused by enteropathogenic microorganisms.
- pigs are most susceptible to gastrointestinal infections at three points in their lives: when they are newborn, when they are being weaned and when they have just been weaned, since their digestive system is under stress, being forced to adapt to changed feeding conditions.
- the composition of the invention is therefore advantageously administered to suckling or weaning pigs.
- older pigs .(porkers) may also succumb to gastrointestinal diseases which may spread very quickly to an entire herd of the pigs thereby causing substantial economic loss due to death or considerable loss of weight.
- the composition may be formulated in any of the ways described above, but is preferably adapted to be sprayed or sprinkled in the environ ment of the pigs, or Is in the form of a suspension in an oily or aqueous medium such as the drinking water, an electrolyte solution or a reconstituted sowmilk replacer.
- the composition When the composition is sprayed or sprinkled in the environment of the pigs, the pigs will take up the bacteria when they root about in the sty, the bacteria colonizing the intestinal epithelium and competing with enteropathogens taken up in a similar way.
- the composition may also advantageously be mixed with the feed.
- the composition is preferably the freeze-dried or spray-dried powder described above.
- the amount of lactic acid bacteria per dosage of the composition is in the range of 10 4 -10 12 , preferably 10 6 -10 10 , colony-forming units.
- the composition is suitably administered 1-3 times a day for a period of up to 14 days, the period being to some extent determined by the level of contamination in the sty or by the condition of the pigs, i.e. whether the composition is to be used therapeutically or prophylactically.
- the lactic acid bacteria of the invention may optionally be administered concomitantly with or subsequent to antibiotic therapy in order to counteract the unfavourable effect of antibiotic treatment that the healthy intestinal flora is killed, thus giving pathogens ample opportunity to colonize the intestinal epithelium without being held in check by other organisms in the intestinal environment.
- the composition of the invention may be administered to a gestating or lactating sow in an amount sufficient to provide a therapeutically effective amount of the bacteria in the environment of the sow.
- This form of administration therefore has the same effect as spraying or sprinkling the bacteria directly in the environment of the pigs.
- the amount of bacteria administered is in the range of 10 5 -10 12 , preferably 10 7 -10 11 , viable colony-forming units per dosage.
- the bacteria are suitably administered 1-3 times a day for a period of up to 28 days, the period being to some extent determined by the level of contamination by pathogens in the sty.
- the invention is described in further detail in the following examples which should not be construed as limiting in any way to the scope of the invention.
- the fermentation profile of the bacteria is shown in Tables 2, 2a and 3.
- the profiles were performed using a commercially available test system (API-50CH), Tables 2 and 2a, and using a modified MRS (Oxoid CM 359) medium and incubation method according to Bergey's Manual of Systematic Bacteriology, Volume 2, 1986, Table 3.
- API-50CH commercially available test system
- MRS Oxoid CM 359
- the fermentation profiles of both tests were compared to the fermentation patterns described in Bergey's Manual 1986.
- eight more criteria shown in Table 2a were also taken into account in the identification, resulting in 30 criteria according to Bergey's Manual .
- the Boehringer Mannheim Kit used to determine the concentration of L- and D-lactic acid in the growth medium consists of a) glycylglycine. buffer, L-glutamic acid and stabilizers; b) ⁇ -nicotlnamide-adenine dinucleotide (NAD) ; c) 1100 U of glutamatepyruvate transaminase (GPT); and d) 3800 U of L-lactate dehydrogenase (for L-lactic acid) or D-lactate dehydrogenase (for D-lactic acid) (LDH) , in separate containers.
- glycylglycine. buffer, L-glutamic acid and stabilizers b) ⁇ -nicotlnamide-adenine dinucleotide (NAD) ; c) 1100 U of glutamatepyruvate transaminase (GPT); and d) 3800 U of L-lactate dehydrogenase (for
- the sample. (0.1-10 ml) is pipetted into a cuvette (1 cm light path) containing a)+b)+c).
- the absorbance is read at 340 nm after which d) is added initiating the following reaction:
- LDH 1 L-lactate + NAD ⁇ pyruvate + NADH + H + .
- the amount of NADH formed in the above reaction is stoichiometric with the concentration of lactic acid.
- the absorbance is measured at 340 nm after completion of the reaction (about 10 minutes).
- the difference in absorbance before and after reaction is calculated and compared to that of a blank (a cuvette not containing any sample).
- the amount of lactic acid in the sample is then calculated according to the following formulae:
- MW molecular weight of the substance to be assayed
- d light path (cm)
- a characteristic considered important for a probiotic strain is the ability to attach to the cells of the gastrointestinal tract . This attachment will enable the bacteria to multiply and colonize the stomach and the intestinal tract, thus contributing to maintaining a well-balanced microflora in the digestive tract.
- test is a slight modification of a test described by Fuller et al. (Appl. and Environ. Microbiol. 35 (3), 1978).
- Newborn piglets which had not yet been fed were killed by an intracardiac overdose of pentobarbitone.
- the stomach was opened by a slit along the greater curvature, and the oesophageal and gastric walls were gently washed with phosphate buffered saline (PBS), pH 7.3.
- PBS phosphate buffered saline
- Squamous epithelial cells from the pars oesophagea were brushed off into 2.5 ml of PBS and homogenized gently. This preparation can be stored frozen at -20°C.
- the bacteria (all Lactobacilli) were grown overnight at 37°C in MRS medium (Oxoid CM 359) .
- the test culture was diluted or centrifuged and resuspended in PBS, and the total count was adjusted by using a counting chamber to about 5x10' to 1x10° cells per ml.
- 0.2 ml of the epithelial cell suspension was mixed with 0.05 ml of bacterial suspension to give a ratio of approximately 100 bacteria to I epithelial cell.
- the mixture was rotated at 37°C for 30 minutes and examined for adhesion by phase-contrast microscopy. At least 5 cells were exam ined.
- the bacteria can ferment the carbohydrates available in the partially decomposed feed, i.e. lactose from sowmilk and glucose, maltose and, to some extent, starch from the weaning feed.
- One of the characteristics which is also considered important for a probiotic organism is the ability to produce lactic acid, thus reducing the pH, both in the stomach and in the upper part of the small intestine.
- the five strains in question have been selected for acidification activity in media resembling partially decomposed feed.
- the medium (called MRS-P) was a modified MRS medium in which the glucose had been replaced by a mixture of maltose and soluble starch in equal amounts.
- the composition of the medium was as follows:
- pH 6.2 From an overnight MRS culture of the strain in question, 0.10 ml was inoculated into 10 ml of MRS-P. After incubation at 37°C for up to 48 hours in an atmosphere containing 10% CO 2 in H 2 , the pH was measured.
- the amount of bile produced during 24 hours varies with the feeding time and the content of fat in the feed. In pigs the bile concentration is unlikely to exceed 0.9% in the contents of the small intestine. The strains in question have been selected for their tolerance to bile.
- the bile tolerance was measured as the acidification activity in MRS (Oxoid CM 359) containing 0.9% of bile, added as 0.9 g of Bactooxgall (Difco B 128) per 1000 ml of broth.
- An important criterion for a probiotic strain is the ability to survive the passage of the stomach.
- the HCl production in a pig's stomach increases during the first period of the piglet's life until it is fully developed after approximately two months.
- the pH of the stomach varies greatly, depending on the nature and amount of the stomach contents. The pH Is rarely less than 4.5 In a stomach containing feed, but pH in an empty stomach of a pig can be as low as 1.0-2.0.
- strains in question have been selected for their acid tolerance by testing the survival in a PBS medium of pH 2.5.
- Dilution series and plating on MRS was carried out at time 0 and 1 hour, and the log reduction was determined.
- the five selected strains have been tested for susceptibility to a number of growth promoters and antibiotics frequently used as feed additives.
- the susceptibility was measured as the minimum inhibitory concentration (MIC) values by inoculating the organisms into two-fold dilution series of the individual additives in an MRS broth.
- the bacterial concentration was approximately 5 ⁇ 10 5 /ml. The results are shown in Table 7.
- Flavofosfolipol 5 0.6 10 10 2.5
- the five selected strains which were all rifr were plated on solid MRS medium containing 50 ⁇ g/ml rifampicin and Incubated anaerobically for 48 hours at 37°C.
- One colony of each strain was grown anaerobically in liquid MRS medium containing 50 ⁇ g/ml rifampicin for 18 hours at 37°C after which the strains were mixed in a ratio of 1:1:1:1:1 CFU/ml to a total of 4-10 ⁇ 10 8 CFU/ml.
- a pig starter feed (Pri-mor from A/S Korn- og Foderstof Kompagniet, Denmark) were crushed and mixed with 75 ml of water.
- the feed additives were added immediately prior to the addition of 2.5 ml (1.6 ⁇ 10 7 CFU/ml) of the mixed bacterial cultures.
- the mixture was incubated with stirring for 4 hours at 37°C after which the pH was measured and dilution series were prepared.
- the incubated mixture was plated on solid MRS medium containing 50 ⁇ g/ml rifampicillin.
- Olaquindox 20 ppm 6.4 ⁇ 10 7 5.66
- Flavomycin 25 ppm 5.3 ⁇ 10 7 5.69
- Tylosin 40 ppm 3.6 ⁇ 10 7 5.82
- Virginiamycin 50 ppm 1.3 ⁇ 10 7 5.83
- Lactobacilli It is characteristic of some Lactobacilli to be able to produce H 2 O 2 which may show an inhibitory effect against other microorganisms.
- the probiotic lactic acid bacteria should have a brief generation time.
- the selected strains When grown In MRS medium at 40°C under anaerobic conditions, the selected strains showed the generation times indicated in Table 10.
- One group from each litter was housed together as a treatment group, and the remaining three groups were housed together as the control group.
- Both groups were housed in pens heavily contaminated with 0.5 1 each of a fully outgrown hemolytic E. coli 0149/K88 towards which the pigs were known to be sensitive.
- E. coli 0149/K88 was isolated from all animals at some time during the period, peaking on days 7-11.
- the average daily weight gain of the Lactobacillus treated pigs was more than twice as high as that of the untreated group, indicating that the severity of the diarrhoeal outbreaks was reduced by the administration of the Lactobacillus cultures.
- the field trial included 1260 newly weaned pigs from four herds, all suffering from weaning diarrhoea induced by E. coli 0149.
- 562 pigs were treated with a freeze-dried mixture of four probiotic strains (SS129, SS131, SS151 and SS258) which was administered as a "top dressing" in a dosage of 5 ⁇ 10 9 colony-forming units/pig/day for the first ten days of weaning.
- 437 pigs were treated conventionally with antibiotics, chemotherapeutic agens and/or a high dosage of zinc (positive control).
- the remaining 261 pigs did not receive any treatment (negative control).
- Table 12 The results are shown in Table 12 below. TABLE 12
Abstract
Lactic acid bacteria isolated from the gastrointestinal tract of pigs are selected for their ability to survive in a gastrointestinal environment, i.e., for their bile and acid tolerance, and for their ability to adhere to pig gastrointestinal epithelium. The thus selected bacteria may be included in a fermented milk product intended for human consumption or in a veterinary composition for preventing or treating pig gastrointestinal diseases.
Description
LACTIC ACID BACTERIA FOR USE IN FERMENTED MILK PRODUCTS AND VETERINARY COMPOSITIONS
FIELD OF INVENTION
The present invention relates to lactic acid bacteria isolated from the gastrointestinal tract of pigs and a fermented milk product comprising such bacteria, as well as to a powder and a veterinary Composition comprising the bacterium and the use thereof in the. prophylaxis or treatment of pig gastrointestinal diseases.
TECHNICAL BACKGROUND
Fermented milk products have long been known to be a beneficial component of human diet as they combine the nutritive value of milk in terms of protein content, including a favourable amino acid composition, content of fat and overall energy content (slightly less than in unfermented milk due to the conversion of lactose to lactic acid through the action of lactic acid bacteria) and the increased digestibility established for fermented milk products (Livia Aim, "The Effect of Fermentation on Nutrient in Milk and some Properties of Fermented Liquid Milk Products", Naringsforskning 27 , 1983, pp. 2-8). The improved digestibility is obtained by precipitation of the milk protein (casein) into fine curd particles which are more easily digested by the enzymes present in the digestive tract than the large casein particles resulting from the action of gastric juice on unfermented milk. Furthermore, the fermentation process causes a significant hydrolysis of the proteins present in the milk into smaller peptides and free amino acids, and this so-called pre-digestion of the proteins makes it easier to degrade them by the digestive enzymes. Lactic acid fermentation also tends to favourably affect the utilization of calcium in the body in the form of calcium lactate which is more easily absorbed in the body.
Apart from the improved utilization of the nutrient components in milk which in itself would speak in favour of the consumption of fer
mented milk products, the lactic acid bacteria present In the fermented milk may inhibit the growth of pathogenic or potentially pathogenic microorganisms in the intestinal tract by producing various organic acids (primarily lactic acid and, to a smaller extent, acetic, propionic and formic acid) which lower the intestinal pH so as to inhibit acid-sensitive organisms. Some lactic acid bacteria also produce antimicrobial substances known as biocines which contribute to controlling the growth of pathogens in the intestines. A high concentration of lactic acid bacteria in the intestines may also be employed prophylactically to protect against attacks from pathogenic bacteria.
Ingestion of fermented milk products may therefore be advantageous in order to maintain a good biological balance of the intestinal flora of a healthy person and possibly also to redress the imbalance in the intestinal flora occasioned by various conditions such as intestinal diseases and disorders (e.g. diarrhoea), functional disorders of the digestive tract, or the after-effects of antibiotic treatment and radiation therapy. By ingesting a fermented milk product, the normal Intestinal flora may be regenerated.
Fermented milk products comprising lactic acid bacteria and alleged to exert a beneficial effect by maintaining the normal balance of the intestinal flora are commercially available and are described by, for instance, Frank V. Kosikowski in Cheese and Fermented Milk Foods , 2nd Ed., 1978, pp. 37-48. To the present inventors' best knowledge, however, the ability of the bacteria used in these products to survive in a gastrointestinal environment has not been adequately documented.
One object of the present invention Is therefore to provide lactic acid bacteria which show advantageous properties with respect to survival in the gastrointestinal tract when included in a fermented milk product intended for human consumption.
Another object of the present invention is to provide lactic acid bacteria with useful properties for the prophylaxis or treatment of pig gastrointestinal diseases.
Gastrointestinal infections frequently occur in pigs, especially young pigs, resulting in retardation of the growth rate and even death of some of the infected pigs. Enteric diseases in pigs may be of bacterial, viral or protozoal origin and are, in the case of bacteria, initiated by a colonization of the gastrointestinal epithelium with pathogenic organisms which compete with the normal intestinal flora and, if successfully established, produce (depending on the species) exotoxins (enterotoxins) which in sufficient quantities, that is when the organism producing them has ousted the normal bacterial flora from the intestines, produce a variety of disease symptoms in the host, notably diarrhoea leading to an occasionally fatal loss of fluid from tissues and in a decreased feed consumption as well as utilization of the feed. Enteropathogenic organisms are easily transmitted from one pig to another through their presence in the faeces of infected animals present in their environment, and therefore the disease may very quickly be transmitted from the initially infected animal to the rest of the herd. Hence, gastrointestinal infections present a major source of economic loss to pig breeders.
Gastrointestinal diseases in pigs have usually been combated with antibiotics. Thus, antibiotics have been administered prophylactically to neonatal pigs or to gestating sows before farrowing. However, this procedure suffers from the disadvantage that it eliminates the natural intestinal flora, making the animals more vulnerable to invasion by opportunistic pathogens which colonize the intestines more rapidly than the natural microflora. This may, in turn, give rise to bacterial infection after the antibiotic treatment has ceased. Another frequent result of antibiotic treatment is the development of antibiotic-resistant strains of the pathogens. Furthermore, especially when therapeutic doses of antibiotics are administered to older pigs or porkers, residual amounts of the antibiotics may be present in the meat of slaughtered animals; this is undesirable since it may lead to allergic reactions in humans consuming the meat and to the development of antibiotic-resistant strains of human pathogens after exposure of these to low dosages of the antibiotics in question. For these reasons, health authorities in most countries have prohibited the presence of residual antibiotics in meat intended for human consumption.
Alternative procedures involving the use of non-pathogenic bacteria such as lactic acid bacteria have therefore been suggested as a replacement of or supplement to antibiotic treatment in case of animal, Including human, gastrointestinal infections. Thus, US 3,320,130 discloses a process for preparing a medicament comprising separately culturing L. acidophilus and a non-pathogenic strain of E. coli on milk containing gastro-pyloric mucin and lysine, arginlne and histidine. The separate cultures are lyophilized and mixed. Both organisms were Isolated from the faeces of a healthy baby, and the medicament is, presumably, intended for human use. It Is suggested that these bacteria will compete successfully with the other intestinal flora.
US 3,953,609 discloses a method of changing the digestive system bacteria in animal by orally feeding the animals live Lactobacillus lactis NRRL B-5628 in an amount of 1×1010 cells/kg body weight/day to reduce the number of other gastrointestinal tract bacteria. The purpose is to provide prophylaxis or treatment of colibacillosis in animals such as swine, cattle and poultry. The bacterial strain was isolated from human faeces.
US 4,314,995 discloses a method of treating infections by local administration of the Lactobacillus strains FRI 1946, 2779, 2780, 2781 or 2782, optionally together with an antibiotic. Among the diseases suggested for treatment in the patent by means of these bacteria are gastritis and enteritis for which applications the bacteria are preferably administered together with antibiotics. The bacteria are stated to be bile resistant, but their origin is not indicated. The bacteria appear to be intended for use in humans only.
EP 203 586 discloses the use of Lactobacillus fermentum ATCC 53113 or mutants thereof for treating gastrointestinal diseases in domestic animals such as pigs, cows, sheep, goats and horses. The strain is indicated to have been isolated from the gut of a healthy newborn Pig.
SUMMARY OF THE INVENTION he present inventors have now isolated probiotic lactic acid bacteia from the digestive tract of pigs which bacteria have been careully selected for properties which are useful when the organisms re to be employed in fermented milk products for the prophylaxis or reatment of pig gastrointestinal infections. ccordingly, the present invention relates to a lactic acid bacterium hich is viable in the gastrointestinal tract of human beings and igs, the bacterium being isolated from the gastrointestinal tract of pig and selected according to the following criteria:
adhesion to pig gastrointestinal epithelial tissue after incubaion of bacteria with pig epithelial cells in a ratio of 100:1 inhosphate buffered saline at 37°C for 30 minutes,
production of lactic acid as determined by
i) growth in MRS (Oxoid CM 359) medium, pH 6.2, for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction to at least 4.0, or
ii) growth in 9.5% reconstituted skimmilk, pH 6.3-6.4, for up to 48 hours at 37ºC in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction to at least 5.2, or
iii) growth in modified MRS medium without glucose, pH 6.2, containing equal amounts of maltose and soluble starch for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction to at least 4.5, or
iv) defined as the production of at least 10 g/l of lactic acid (D- and L-forms) when grown in MRS medium, pH 6.2, for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in
H2,
c) bile tolerance as determined by growth in MRS medium, pH 6.2, supplemented with 0.9% bile for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction comparable to the one defined in b) (i)-(iii),
d) acid tolerance as determined by a reduction in the number of colony-forming units/ml after incubation for 1 hour at 40°C and a pH of 2.5 not exceeding 3.2 log units, preferably less than 1 log unit,
e) a generation time of about 65 minutes, preferably 30-50 minutes, when grown in MRS medium at 40°C under anaerobic conditions,
or a functionally equivalent mutant thereof.
In the present context, the term "probiotic" is used to indicate cultures of non-pathogenic gastrointestinal bacteria or compositions containing such cultures which, after the ingestlon of effective doses, may survive or even become established in the gastrointestinal tract and thereby preserve or enforce the function of the microflora as a barrier against the colonization of the epithelium by pathogenic organisms.
In order to exert the above-described beneficial effects both with respect to maintaining or restoring a healthy balance of the gastrointestinal microflora and with respect to inhibiting the growth of pathogenic or potentially pathogenic organisms, It is essential that the bacteria of the invention are capable of surviving the conditions prevailing in the gastrointestinal tract. The criteria according to which the bacteria of the invention have been selected have primarily been employed to achieve this overall effect. Thus, contrary to known fermented milk products allegedly producing these effects on Ingestion, the lactic acid bacteria of the invention have been systematically screened for their viability under gastrointestinal conditions in pigs. Due to the well-known similarities between the human and porcine digestive systems, the fact that the bacteria of the invention have been shown to establish themselves in the intestines of pigs renders probable their ability to survive in the human gastrointestinal tract as well. When the bacteria of the invention are inge
sted primarily to maintain a favourable balance of the intestinal microflora, survival of the bacteria in the digestive tract is the most important selection criterion as regular ingestion of a fermented milk product containing the bacteria will usually be sufficient to ensure a sufficient number of the bacteria in the intestines to provide a favourable regulation of the intestinal flora.
In connection with research leading to the present invention, it has been found that lactic acid bacteria isolated from the intestinal flora of the same animal species as the one to which it will eventually be administered for therapeutic purposes show superior properties with respect to therapeutic effect. This may, presumably, be ascribed to the fact that the bacteria have already adapted to the conditions prevailing in the intestines of the animal species in question so that they will be able to colonize and compete successfully with the other intestinal flora and establish itself in the intestines. To the best of the present inventors' knowledge, this finding has not previously been reported, and in the prior literature nobody appears to have speculated that it might be important for obtaining the desired effect, cf. EP 203 586 which although it discloses an organism isolated from a pig which is used to treat diarrhoea in pigs , also indicates that the same organism may be used for treating animals of other species .
In particular when the bacteria of the invention are intended to be used therapeutically, however, it has been found to be advantageous that they show good adhesion properties since this improves their ability to colonize the gastrointestinal mucosa and compete successfully with the pathogens or potential pathogens present in the intestines, thus obtaining a favourable balance of the gastrointestinal microflora. The adhering bacteria form a layer on the epithelium and prevent access of the pathogens to the receptors present on the epithelial cells. The bacteria preferably adhere to pig gastrointestinal tissue in a number of at least 4, preferably at least 16, most preferably at least 50, per epithelial cell. The production of lactic acid is another important selection criterion since most pathogens show a significantly decreased growth rate in the presence of acid. Bile and acid tolerance are also essential for a probiotic bacterium
to be employed successfully in the intestines, in particular the upper small intestines in order to be able to survive passage of the stomach and Intestines, and possibly to colonize the epithelium In the vicinity of the biliary tract. Since most pathogens tend to multlply very quickly, It is also essential that the lactic acid bacteria employed as the probiotic organisms have a brief generation time so that they may compete with the pathogens in the intestines.
Certain lactic acid bacteria have been found to produce one or more antimicrobial agents such as hydrogen peroxide. Such substances are known to possess an inhibitory effect on a variety of microorganisms and therefore supplement the effect of pH decrease ascribable to the production of lactic acid.
Mutants of the bacteria may either occur spontaneously (as is often the case in nature) or be produced deliberately such as by treatment with a chemical mutagen such as mitomycin C, 5-bromouracil, methylmethane sulphonate, nitrogen mustard and the nitrofurans, ionizing radiation, ultraviolet radiation, or by applying recombinant DNA techniques. The term "functionally equivalent" should be taken to mean a mutant which shows similar properties to the parent strain with respect to establishing itself and competing with the pathogens present in the intestines at the time the bacteria are administered or entering the Intestines at some later point.
Ingestion of a fermented milk product containing lactic acid bacteria of the invention for the purpose of regulating digestive functions or prophylactic or therapeutic administration of a lactic acid bacterium of the invention promotes the establishment of the normal, healthy microflora in the Intestines thereby creating or recreating a balanced intestinal environment where enteropathogens have difficulties in establishing themselves. As a result of this, it may, in case of actual gastrointestinal infections, furthermore be advantageous to administer the lactic acid bacteria concomitantly with or subsequently to antibiotic treatment in order to restore a healthy balance of the intestinal flora. It is, however, preferred that antibiotic treatment of pig gastrointestinal tract infections be dispensed with
altogether and replaced by administration of the lactic acid bacteria of the invention.
DETAILED DISCLOSURE OF THE INVENTION
Probiotic bacteria useful for the present purpose may, in principle, be any lactic acid bacteria isolated from porcine gastrointestinal epithelium, preferably the epithelium of healthy pigs. Suitable strains may be selected after isolation by screening procedures comprising testing for adhesive properties, production of lactic acid, acid and bile tolerance and generation time as described in further detail in Examples 1-5 and 8 below. For treating pig gastrointestinal infections in particular, the bacteria may be isolated from pigs of varying ages so as to ensure the availability of strains which are able to colonize the epithelium at different stages of the pigs' lives. Specific examples of lactic acid bacterial strains which may be employed in the present invention include strains selected from the genus Lactobacillus , e.g. L. acidophilus/L . gasseri isolated from the duodenum of a suckling pig; L. salivarius subsp. salivarius isolated from the jejunum of a weaning pig; L . acidophilus/L . gasseri isolated from the ileum of a weaning pig; L . crispatus isolated from the jejunum of a suckling pig; and L. salivarius subsp. salivarius isolated from the pars oesophagea of a suckling pig.
Samples of thus isolated strains of these Lactobacillus species were deposited in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure on 22 December, 1987 in the Deutsche Sammlung von Mikroorganismen, Mascheroder Weg IB, 3300 Braunschweig, Federal Republic of Germany, with the following accession numbers:
L. acidophilus/L . gasseri SS28 DSM 4324
L. salivarius subsp. salivarius SS129 DSM 4325 L. acidophilus/L. gasseri SS131 DSM 4326
L . crispatus SS151 DSM 4327
L. salivarius subsp. salivarius SS258 DSM 4328
It will, however, be evident to persons skilled In the art that other lactic acid bacterial strains may be isolated in a similar fashion, using the selection criteria indicated above and the procedures described in the examples, without departing from the spirit and scope of the present invention.
For use in a fermented milk product, the two Lactobacillus salivarius strains indicated above have been found to be particularly suitable as they not only provide the beneficial effects described above, but also result in an agreeable taste of the product.
Once Isolated, the bacteria may be propagated by growing the selected strain or strains in a suitable culture medium under anaerobic conditions for a period of time sufficient to provide at least 106 viable bacteria/ml of medium and harvesting the resulting bacteria from the medium. The cultivation temperature will typically be about 37°C, and the pH in the range of about 5.5-6.5.
In another aspect, the present invention relates to a liquid or frozen concentrate comprising lactic acid bacteria of the invention. Although it is theoretically possible to use the culture medium containing the bacteria directly, it is generally preferred to produce a bacterial concentrate in order to obtain a higher count of bacteria for administration or inoculation. The concentrate may be prepared by, for instance, centrifugation or filtration. The concentrate may suitably comprise 1×104-1×1012 viable colony-forming units/ml. The concentrate may contain a mixture of two or more of the Lactobacillus strains indicated above.
In a further aspect, the present invention relates to a freeze-dried or spray-dried powder comprising a lactic acid bacterium as described above. In this case, too, it is in theory possible to dry the bacterial cultures as grown, but it is preferred to concentrate the bacteria before drying for the reason indicated above. To ensure a sufficient viability of the bacteria, it is preferred to add a stabilising or cryoprotective agent to the concentrate before drying as for instance disclosed in US 3,897,307. The resulting dried powder preferably comprises 104-1012 viable colony-forming units/g. It may be
an advantage that the powder comprises a mixture of two or more lactic acid strains such as those listed above, in order to secure a broad-spectrum activity of the powder when used as or in a preparation to be administered to pigs of varying ages.
In a still further aspect, the invention relates to a fermented milk product which comprises a lactic acid bacterium of the present invention. The product Is primarily intended for human consumption, and although it is primarily ingested for its nutritive value, it may be particularly useful for dietary purposes, i.e. for its favourable influence on digestive properties ascribable to the ability of the lactic acid bacteria to inhibit the growth of pathogenic or potentially pathogenic microorganisms. The fermented milk product of the invention may contain a mixture of two or more of the Lactobacillus strains listed above, and preferably also contains a Bifidobacterium sp. such as B . bifidum or B . longum, as well as L . acidophilus .
The fermented milk product may be prepared by inoculating milk with a culture of the bacterium of the invention in a manner known per se , e.g. as described by A.Y. Tamine and R.K. Robinson in Yoghurt Science and Technology, 1985, preferably in the form of the liquid or frozen concentrate or freeze-dried or spray-dried powder described above. Consequently, the present invention also relates to the use of the lactic acid bacterium or a liquid or frozen concentrate or freeze- dried or spray-dried powder containing it for the production of a fermented milk product. The inoculation level is typically in the range of 1×105-1×108 bacteria/ml of milk, such as 5×106 bacteria/ml.
The lactic acid bacteria of the invention have been found capable of reducing the occurrence and/or severity of gastrointestinal tract infections in pigs caused by enteropathogenic microorganisms. The term "reducing the occurrence" is understood to mean that there are fewer cases of gastrointestinal infections both among individual pigs within each herd and among herds on the same farm, relative to pigs which have not been treated with the lactic acid bacteria of the invention. The gastrointestinal tract infections which may be prevented or treated by administering the bacteria of the invention may be any infections resulting from the presence and multiplication of
enteropathogenie microorganisms in the Intestines, e.g. diarrhoeas, scours, etc. Examples of enteropathogens are E. coli and rotavirus.
In a still further aspect, the present invention relates to a veterinary composition for the prophylaxis or treatment of gastrointestinal tract infections in pigs caused by enteropathogenie microorganisms, the composition comprising a lactic acid bacterium as described above and an excipient or carrier. The composition should preferably comprise 103-1012 viable colony-forming units/g since in this range a sufficient number of bacteria will normally survive the passage of the pigs stomach to colonize the intestinal epithelium in sufficient numbers to compete successfully with the pathogens or other microorganisms present.
The composition may be formulated according to conventional veterinary practice as a powder, granulate, tablet, capsule, paste, gel, drench, mixture or suspension. Solid formulations, i.e. powders, granulates, tablets and capsules, may contains fillers, e.g. sugars, sorbitol, mannitol and silicic acid; binders, e.g. cellulose derivatives such as carboxymethyl cellulose and polyvinylpyrrolidone; disintegrants, e.g. starch, sodium bicarbonate and calcium carbonate; lubricants, e.g. magnesium stearate, talc and calcium stearate.
Semi-solid formulations, i.e. pastes or gels, may comprise a gelling agent such as an alginate, gelatin, carrageenan, tragacanth gum and pectin, a mineral oil such as liquid paraffin, a vegetable oil such as corn oil, sunflower oil, rape oil and grape kernel oil, as well as a thickener such as a starch, gum, gelatin, etc. Liquid formulations, i.e. drenches, mixtures and suspensions, may comprise a liquid or oily vehicle, e.g. water (favourably the drinking water of the pigs to which the composition is administered), an electrolyte solution (often given to pigs to compensate for the electrolyte loss caused by the loss of fluids from tissue which is characteristic of diarrhoea) or reconstituted sowmilk replacer. Oily vehicles comprise a mineral oil such as liquid paraffin, a vegetable oil such as corn oil, sunflower oil, rape oil, grape kernel oil, etc. The freeze-dried or spray-dried powder of the invention may be suspended in the liquid vehicle in accordance with usual practice.
The powder formulation may advantageously be the freeze-dried or spray-dried powder described above, either in itself or formulated with one or more further excipients.
The solid formulations may be provided with a coating to protect the bacteria from gastric conditions so that they will more easily survive the passage of the stomach. The coating should be one which is degradable in a gastrointestinal environment. The coating is preferably one which is soluble in the stomach (though only gradually so that the protective effect will be maintained) or in the upper part of the small intestines. Examples of suitable coatings are alginates or lipids.
The composition of the invention may also comprise a mixture of two or more lactic acid bacterial strains such as the strains listed above. Apart from the lactic acid bacteria, the composition may further comprise other active agents such as antibiotics, chemical growth promoters, or microorganisms or enzymes which have a growth promoting effect.
In a still further aspect, the present invention relates to the use of a lactic acid bacterium as defined above for preparing a veterinary composition for the prophylaxis or treatment of gastrointestinal tract infections in pigs caused by enteropathogenic microorganisms.
It is known that pigs are most susceptible to gastrointestinal infections at three points in their lives: when they are newborn, when they are being weaned and when they have just been weaned, since their digestive system is under stress, being forced to adapt to changed feeding conditions. The composition of the invention is therefore advantageously administered to suckling or weaning pigs. However, older pigs .(porkers) may also succumb to gastrointestinal diseases which may spread very quickly to an entire herd of the pigs thereby causing substantial economic loss due to death or considerable loss of weight.
The composition may be formulated in any of the ways described above, but is preferably adapted to be sprayed or sprinkled in the environ
ment of the pigs, or Is in the form of a suspension in an oily or aqueous medium such as the drinking water, an electrolyte solution or a reconstituted sowmilk replacer. When the composition is sprayed or sprinkled in the environment of the pigs, the pigs will take up the bacteria when they root about in the sty, the bacteria colonizing the intestinal epithelium and competing with enteropathogens taken up in a similar way. For weaning pigs or porkers, the composition may also advantageously be mixed with the feed. The composition is preferably the freeze-dried or spray-dried powder described above.
When the composition is intended for oral use, the amount of lactic acid bacteria per dosage of the composition is in the range of 104-1012, preferably 106-1010, colony-forming units. At this dosage level, the composition is suitably administered 1-3 times a day for a period of up to 14 days, the period being to some extent determined by the level of contamination in the sty or by the condition of the pigs, i.e. whether the composition is to be used therapeutically or prophylactically.
The lactic acid bacteria of the invention may optionally be administered concomitantly with or subsequent to antibiotic therapy in order to counteract the unfavourable effect of antibiotic treatment that the healthy intestinal flora is killed, thus giving pathogens ample opportunity to colonize the intestinal epithelium without being held in check by other organisms in the intestinal environment.
Alternatively, the composition of the invention may be administered to a gestating or lactating sow in an amount sufficient to provide a therapeutically effective amount of the bacteria in the environment of the sow. This form of administration therefore has the same effect as spraying or sprinkling the bacteria directly in the environment of the pigs. The amount of bacteria administered is in the range of 105-1012, preferably 107-1011, viable colony-forming units per dosage. At this dosage level, the bacteria are suitably administered 1-3 times a day for a period of up to 28 days, the period being to some extent determined by the level of contamination by pathogens in the sty.
The invention is described in further detail in the following examples which should not be construed as limiting in any way to the scope of the invention.
EXAMPLE 1
Isolation and characterization of Lactobacillus strains
Description of strains
A large number of bacteria were isolated from a number of healthy piglets and weaning pigs from several different swine herds, and after comprehensive screening as described below in Examples 1-5 and 8, the following strains were selected:
SS28 L. acidophilus/L. gasseri isolated from duodenum of a suckling pig.
SS129 L . salivarius subsp. salivarius isolated from jejunum of a weaning pig.
SS131 L . acidophilus/L. gasseri isolated from ileum of a weaning pig.
SS151 L. crispatus isolated from jejunum of a suckling pig.
SS258 L. salivarius subsp. salivarius isolated from pars oesophagea of a suckling pig.
Fermentation pattern
The fermentation profile of the bacteria is shown in Tables 2, 2a and 3. The profiles were performed using a commercially available test system (API-50CH), Tables 2 and 2a, and using a modified MRS (Oxoid CM 359) medium and incubation method according to Bergey's Manual of Systematic Bacteriology, Volume 2, 1986, Table 3.
For identification, the fermentation profiles of both tests were compared to the fermentation patterns described in Bergey's Manual 1986. In addition to the fermentation patterns of the 22 carbohydrates from the API-50CH used for comparison with Bergey's Manual , eight more criteria shown in Table 2a were also taken into account in the identification, resulting in 30 criteria according to Bergey's Manual .
Table 2
Fermentation patterns as recorded by API-50CH
Medium Reaction
SS28 SS129 SS131 SS151 SS258
Glycerol - - - - - Erythritol - - - - -
) D-Arabinose - - - - -
X) L-Arabinose - - - - - x) Ribose - - - - -
) D-Xylose - - - - - x) L-Xylose - - - - -
Adonitol - - - - - β Methyl-Xyloside - - - - - x) Galactose + + + + + x) D-Glucose + + + + + x) D-Fructose + + + + + x) D-Mannose + + + + +
L-Sorbose - - - - - x) Rhamnose - + - - +
Dulcitol - - - - -
Inositol - - - - - x) Mannitol - + - - + x) Sorbitol - + - - - α Methyl-D-Mannoside - - - - - α Methyl-D-Glucoside - - - - -
N Acetyl Glucosamine + + + + + x) Amygdaline + - - + -
Arbutine + - - + - x) Esculine + - + + - x) Salicine + - - + - x) Cellobiose + - + + - x) Maltose + + + + + x) Lactose + + + + + x) Melibiose + + - - + x) Saccharose + + + + + x) Trehalose + - + - +
Inuline - - - - - x) Melezitose - - - - - x) D-Raffinose + + + - +
Amidon + - + + -
Glycogene - - - - -
Xylitol - + - - + β Gentibiose + - + + -
D-Turanose - - - - -
D-Lyxose - - - - -
D-Tagatose - - - - -
D-Fucose - - - - -
L-Fucose - - - - -
D-Arabitol - + - - +
* The Boehringer Mannheim Kit (Cat. No. 139084) used to determine the concentration of L- and D-lactic acid in the growth medium consists of a) glycylglycine. buffer, L-glutamic acid and stabilizers; b) β-nicotlnamide-adenine dinucleotide (NAD) ; c) 1100 U of glutamatepyruvate transaminase (GPT); and d) 3800 U of L-lactate dehydrogenase (for L-lactic acid) or D-lactate dehydrogenase (for D-lactic acid) (LDH) , in separate containers.
The sample. (0.1-10 ml) is pipetted into a cuvette (1 cm light path) containing a)+b)+c). The absorbance is read at 340 nm after which d) is added initiating the following reaction:
LDH 1) L-lactate + NAD ↔ pyruvate + NADH + H+.
The amount of NADH formed in the above reaction is stoichiometric with the concentration of lactic acid. The absorbance is measured at 340 nm after completion of the reaction (about 10 minutes). The difference in absorbance before and after reaction is calculated and
compared to that of a blank (a cuvette not containing any sample). The amount of lactic acid in the sample is then calculated according to the following formulae:
where ΔA - absorbance difference of blank subtracted from that of sample, V = final volume (ml), v = sample volume (ml)
MW = molecular weight of the substance to be assayed, d = light path (cm) , e = absorption coefficient of NADH at 340 nm = 6.3 [1 × mmol-1 x cm-1]
It follows for L-lactic acid
2.018 × ΔA/E [g L-lactic acid/1 sample solution]
Fermentation patterns recorded in Bergey's Modified Medium No. SS28 SS129 SS131 SS151 SS258
1 Gram + + + + +
2 Catalase - - - - -
3 Oxydase - - - -
4 Motility - - - - -
5 Spores - - - - -
6 Strictly aerobic - - - - -
7 Microaerophilic + + + + +
8 Pigment - - - - -
9 Growth, 15°C - - - - -
10 Growth, 45°C + + + + +
11 Starch hydrolysis + - (-) + -
12 Arginine hydrolysis - - - - -
13 Nitrate reduced - - - - -
14 Gelatin liquefaction - - - - -
15 Casein hydrolysis - - - - -
16 Indole - - - - -
17 H2S - - - - -
18 D-Lactic acid + + + + +
19 L-Lactic acid + - + + -
20 Amygdalin + - + + -
21 L(+) Arabinose - - - - -
22 Cellobiose + - + + -
23 Aesculin hydrolysis + - + + -
24 D(-) Fructose + + + + +
25 D(+) Galactose + + + + +
26 D(+) Glucose, acid + + + + +
27 Glucose, gas - - - - -
28 Gluconate - - - - -
29 Lactose + + + + +
30 Maltose + + + + +
31 D(-) Mannitol - + - - +
32 D(+) Mannose + + + + +
33 D(+) Melezitose - - - - -
34 D(+) Melibiose + + + - +
35 D(+) Raffinose + + + - +
36 L(+) Rhamnose - + - - +
37 Ribose - - - - -
38 Salicin + - + + -
39 D(-) Sorbitol - + - - -
40 Sucrose + + + + +
41 Trehalose + - + - +
42 D(+) Xylose - - - - -
Identification
SS28 identified as L. acidophilus/L. gasseri . 100% accordance with Sergey's Manual . No atypical reactions.
SS129 identified as L . salivarius subsp. salivarius . 87% accordance with Bergey 's Manual . Atypical reactions: mannose, trehalose, maltose, sorbitol.
SS131 identified as L. acidophilus/L . gasseri . 97% accordance with Bergey's Manual . Atypical reactions: amygdalin.
SS151 identified as L. crispatus .
100% accordance with Bergey 's Manual . No atypical reactions.
SS258 identified as L. salivarius subsp. salivarius . 97% accordance with Bergey 's Manual .
Atypical reactions: mannose.
EXAMPLE 2
Adhesion to squamous epithelial cells from pars oesophagea
A characteristic considered important for a probiotic strain is the ability to attach to the cells of the gastrointestinal tract . This attachment will enable the bacteria to multiply and colonize the stomach and the intestinal tract, thus contributing to maintaining a well-balanced microflora in the digestive tract.
It has been generally observed that the ability to attach to and colonize the surface of gastric epithelial cells is connected with host specificity (Lin, J.H.-C. and D.C. Savage, "Host specificity of the colonization of murine gastric epithelium by Lactobacilli", FEMS Microbiol . Letters 24 , 1984, pp. 67-71; Tannock, G.W. , O. Szylit, Y.
Duval and P. Raibau, "Colonization of tissue surfaces in the gastrointestinal tract of gnotobiotic animals by Lactobacillus strains", Can. J. Microbiol . 28 , 1982, pp. 1196-1198; Kotarski, S.F., Savage, D.C, "Models for study of the specificity by which indigenous Lactobacilli adhere to murine gastric epithelia" , Inf. and Immun . 26 ,
1979, pp. 966-975; Fuller, R., "Ecological Studies of the Lactobacillus Flora Associated with the Crop Epithelium of the Fowl", J. Appl . Bacteriol . 36, 1973, pp. 131-139).
The five strains in question have been selected for their ability to attach to squamous epithelial cells of pars oesophagea from pig stomachs (Table 4).
Materials and Methods
The test is a slight modification of a test described by Fuller et al. (Appl. and Environ. Microbiol. 35 (3), 1978).
Isolation of epithelial cells from pigs
Newborn piglets which had not yet been fed were killed by an intracardiac overdose of pentobarbitone. The stomach was opened by a slit along the greater curvature, and the oesophageal and gastric walls were gently washed with phosphate buffered saline (PBS), pH 7.3. Squamous epithelial cells from the pars oesophagea were brushed off into 2.5 ml of PBS and homogenized gently. This preparation can be stored frozen at -20°C.
Test for adhesion of bacteria to epithelial cells
The bacteria (all Lactobacilli) were grown overnight at 37°C in MRS medium (Oxoid CM 359) . The test culture was diluted or centrifuged and resuspended in PBS, and the total count was adjusted by using a counting chamber to about 5x10' to 1x10° cells per ml. 0.2 ml of the epithelial cell suspension was mixed with 0.05 ml of bacterial suspension to give a ratio of approximately 100 bacteria to I epithelial cell. The mixture was rotated at 37°C for 30 minutes and examined for adhesion by phase-contrast microscopy. At least 5 cells were exam
ined. Evaluation of the adhesion ability is described as : + = 4-15 bacteria, attached to the surface of 1 epithelial cell; ++ = 16-50 bacteria, attached to the surface of 1 epithelial cell, +++- = ≥ 50 bacteria, attached to the surface of 1 epithelial cell.
TABLE 4
Adhesion of bacteria to epithelial cells
Strain Adhesion
SS28 +++
SS129 +++ SS131 +++
SS151 +
SS258 ++
EXAMPLE 3
Acidification activity
In order to multiply in the intestinal tract, it is important that the bacteria can ferment the carbohydrates available in the partially decomposed feed, i.e. lactose from sowmilk and glucose, maltose and, to some extent, starch from the weaning feed.
One of the characteristics which is also considered important for a probiotic organism is the ability to produce lactic acid, thus reducing the pH, both in the stomach and in the upper part of the small intestine.
The five strains in question have been selected for acidification activity in media resembling partially decomposed feed.
The time it takes to reach the final pH is dependent on the growth conditions of the bacteria before the acidification test.
Materials and methods
Acidification activity in glucose
From an overnight MRS culture of the strain in question, 0.10 ml was inoculated into 10 ml of MRS broth (Oxoid CM 359) of pH 6.2. After incubation at 37°C for up to 48 hours in an atmosphere containing 10% CO2 in H2, the pH was measured.
Acidification activity in lactose
From an overnight MRS culture of the strain in question, 0.10 ml was inoculated Into 10 ml of 9.5% reconstituted skim milk (SKM) which had been UHT treated and pasteurised. After incubation at 37°C for up to 48 hours in an atmosphere containing 10% CO2 in H2, the pH was measured.
Acidification activity in maltose/starch-containing medium
The medium (called MRS-P) was a modified MRS medium in which the glucose had been replaced by a mixture of maltose and soluble starch in equal amounts. The composition of the medium was as follows:
Bacteriological peptone 10.0 g
Bacto soytone 8.0 g
Yeast extract 4.0 g Soluble starch 10.0 g
Maltose 10.0 g
Tween 80 1.0 ml
K2HPO4 2.0 g
Sodium acetate, 3H2O 5.0 g Triammonium citrate 2.0 g
MgSO4, 7H2O 0.2 g
MnSO4, 4H2O 0.05 g
Demineralised water ad 1000 ml
pH = 6.2
From an overnight MRS culture of the strain in question, 0.10 ml was inoculated into 10 ml of MRS-P. After incubation at 37°C for up to 48 hours in an atmosphere containing 10% CO2 in H2, the pH was measured.
Typical final pH values are shown in Table 5.
EXAMPLE 4
Bile tolerance
It is considered important for a probiotic organism to be resistant to the presence of bile in the digestive tract.
The amount of bile produced during 24 hours varies with the feeding time and the content of fat in the feed. In pigs the bile concentration is unlikely to exceed 0.9% in the contents of the small intestine. The strains in question have been selected for their tolerance to bile.
The bile tolerance was measured as the acidification activity in MRS (Oxoid CM 359) containing 0.9% of bile, added as 0.9 g of Bactooxgall (Difco B 128) per 1000 ml of broth.
Method
From an overnight-grown MRS broth of the strain in question, 0.10 ml was inoculated into 10 ml of MRS containing 0.9% of bile.
After incubation at 37°C for up to 48 hours in an atmosphere containing 10% CO2 in H2, the pH was measured.
Typical final values are shown in Table 5.
EXAMPLE 5
Acid tolerance
An important criterion for a probiotic strain is the ability to survive the passage of the stomach. The HCl production in a pig's stomach increases during the first period of the piglet's life until it is fully developed after approximately two months. The pH of the stomach varies greatly, depending on the nature and amount of the stomach contents. The pH Is rarely less than 4.5 In a stomach containing feed, but pH in an empty stomach of a pig can be as low as 1.0-2.0.
The strains in question have been selected for their acid tolerance by testing the survival in a PBS medium of pH 2.5.
Materials and Methods
From a fully outgrown MRS culture, 0.10 ml was inoculated into 10 ml of phosphate buffered saline (PBS), pH 2.50 (adjusted with 0.1 N HCl).
Dilution series and plating on MRS was carried out at time 0 and 1 hour, and the log reduction was determined.
Typical reduction values are shown in Table 6.
TABLE 5
Acidification activities and bile tolerance (incubation at 37°C for up to 48 hours)
Typical final pH values
Medium
MRS MRS + 0.9% MRS-P SKM
Strain of bile
SS28 3.86 4.21 4.02 4.93
SS129 3.72 4.55 4.11 4.43
SS131 3.89 3.92 4.01 5.07
SS151 3.74 3.88 3.75 3.82
SS258 3.69 4.57 4.10 4.36
TABLE 6
Acid tolerance (log CFU/ml reduction in PBS, pH 2.5, 1 hour, 40°C)
Typical reduction values
Strain Log CFU/ml reduction
SS28 3.23
SS129 0.67
SS131 1.92
SS151 0.63
SS258 0.59
EXAMPLE 6
Susceptibility to feed additives
The five selected strains have been tested for susceptibility to a number of growth promoters and antibiotics frequently used as feed additives. The susceptibility was measured as the minimum inhibitory concentration (MIC) values by inoculating the organisms into two-fold dilution series of the individual additives in an MRS broth. The bacterial concentration was approximately 5×105/ml. The results are shown in Table 7.
TABLE 7
MIC values (ppm)
Feed additive SS28 SS129 SS131 SS151 SS258
Avoparcin <1.5 >100 25 100 >100
Olaqulndox >100 >100 >100 (>)100 >100
Carbadox 100 100 100 25 50
Flavofosfolipol 5 0.6 10 10 2.5
Nitrovin 31 >248 248 248 >248
Spiramycin >200 >200 3.1 3.1 6.3
Tylosln >62.5 >62.5 3.9 3.9 3.9
Virginiamycin 7.8 3.9 31 2.0 2.0
Zn-bacitracin 12.5 12.5 <1.6 12.5 12.5
ZnCl2 250 1000 250 1000 1000
EXAMPLE 7
Susceptibility to feed additives present in pig feed
The five selected strains which were all rifr were plated on solid MRS medium containing 50 μg/ml rifampicin and Incubated anaerobically for 48 hours at 37°C. One colony of each strain was grown anaerobically in liquid MRS medium containing 50 μg/ml rifampicin for
18 hours at 37°C after which the strains were mixed in a ratio of 1:1:1:1:1 CFU/ml to a total of 4-10×108 CFU/ml.
25 g of a pig starter feed (Pri-mor from A/S Korn- og Foderstof Kompagniet, Denmark) were crushed and mixed with 75 ml of water. The feed additives were added immediately prior to the addition of 2.5 ml (1.6×107 CFU/ml) of the mixed bacterial cultures. The mixture was incubated with stirring for 4 hours at 37°C after which the pH was measured and dilution series were prepared. The incubated mixture was plated on solid MRS medium containing 50 μg/ml rifampicillin.
The results are shown in Table 8 in which the figures are the average of three experiments.
TABLE 8
Feed additive Amount* CFU/ml pH
Avotan 40 ppm 7.4×107 5.68
Olaquindox 20 ppm 6.4×107 5.66
Carbadox 20 ppm 2.5×107 5.66
Flavomycin 25 ppm 5.3×107 5.69
Nitravin 30 ppm 2 ×107 5.79
Spiramycin 80 ppm 1.8×107 5.84
Tylosin 40 ppm 3.6×107 5.82
Virginiamycin 50 ppm 1.3×107 5.83
Zn-bacitracin 80 ppm 6.5×106 5.79
ZnCl2 100 mM 3.2x107 5.24
Control 0 7.6×107 5.61
* Maximum allowable dosage
It appears from Table 8 that the mixed bacterial cultures survive 4 hours of incubation in the feed containing the ten feed additives although bacterial growth is inhibited to a greater or lesser extent relative to the control.
EXAMPLE 8
H2O2 production
It is characteristic of some Lactobacilli to be able to produce H2O2 which may show an inhibitory effect against other microorganisms.
The five selected strains were tested for the ability to produce H2O2 by a method described by Marshall, V.M. (J. Appl . Bacteriol . 47, 1979, pp. 327-328), slightly modified with respect to the basic growth medium (MRS instead of acetate agar).
The reactions are shown in Table 9.
TABLE 9
Strain H2O2 production
SS28 ++
SS129 - SS131 +
SS151 +
SS258 -
++ = strong production + = weak production
- = no production
EXAMPLE 9
Generation time
In order to be able to compete with the intestinal microflora, the probiotic lactic acid bacteria should have a brief generation time.
When grown In MRS medium at 40°C under anaerobic conditions, the selected strains showed the generation times indicated in Table 10.
TABLE 10
Strain Generation time
SS28 62 minutes
SS129 40 minutes
SS131 50 minutes
SS151 47 minutes
SS258 34 minutes
EXAMPLE 10
Protective effect against experimentally induced E. coli diarrhoea in weaning pigs
The effect of the strains was investigated in weaning pigs challenged with E. coli 0149/K88.
28 pigs of both sexes from 3 litters, age 33-34 days, were removed from their mothers while still nursing and prior to exposure to solid feed. Each litter was divided into two groups, taking the weight and the sex of each animal into account in order to make the two groups as uniform as possible. All the pigs were ear-tagged, and faecal swab samples were taken from each animal.
One group from each litter was housed together as a treatment group, and the remaining three groups were housed together as the control group.
Both groups were housed in pens heavily contaminated with 0.5 1 each of a fully outgrown hemolytic E. coli 0149/K88 towards which the pigs were known to be sensitive.
Each animal from the treatment group received an oral dose (by gavage) of a 10 ml mixture of equal amounts of overnight broths from the five strains = 2×109/dose on arrival (day 1) and twice a day for two weeks. Faecal swab samples were taken from each animal in both groups every morning on days 1-16, 19 and 22.
Results: E. coli 0149/K88 was isolated from all animals at some time during the period, peaking on days 7-11.
From the control group, 7 out of 14 pigs died with the typical symptoms of colienteroxemia. The diagnosis was verified by autopsy, followed by bacteriology and serotyping of E. coli 0149/K88.
From the treated group, only 1 out of 14 pigs died, E. coli 0149/K88 being the primary cause.
χ2 log rank = 5.95, p < 0.015
EXAMPLE 11
Effect on reducing the severity of experimentally induced E. coli diarrhoea In weaning pigs
In the experiment described in Example 10, all surviving pigs in the control group and in the group to which lactic acid bacteria were administered suffered from diarrhoea. In order to assess an effect on the severity of non-fatal cases, the body weights were recorded at the beginning of the experiment and after 14 days. The results are shown in Table 11.
TABLE 11
Mean body weight, kg Average daily Day 0 Day 14 weight gain, g
Control group 9.16 10.60 101
Treatment group 13 8.45 11.70 231
The average daily weight gain of the Lactobacillus treated pigs was more than twice as high as that of the untreated group, indicating that the severity of the diarrhoeal outbreaks was reduced by the administration of the Lactobacillus cultures.
EXAMPLE 12
Field trial with a freeze-dried probiotic mixture
The field trial included 1260 newly weaned pigs from four herds, all suffering from weaning diarrhoea induced by E. coli 0149. 562 pigs were treated with a freeze-dried mixture of four probiotic strains (SS129, SS131, SS151 and SS258) which was administered as a "top dressing" in a dosage of 5×109 colony-forming units/pig/day for the first ten days of weaning. 437 pigs were treated conventionally with antibiotics, chemotherapeutic agens and/or a high dosage of zinc (positive control). The remaining 261 pigs did not receive any treatment (negative control). The results are shown in Table 12 below.
TABLE 12
Group % days with Mortality diarrhoea (%)
Non-treated 11.2 5.4
Zn-antibiotics 0.8 0
Probiotic bacteria 6.3 1.6
It appears from the Table that the frequence of diarrhoea was reduced by 50% by treatment with the lactic acid bacteria of the invention. Likewise, the mortality rate was considerably reduced. In herds with a low infection pressure, a positive effect of the bacteria in the form of an increased daily weight gain throughout the weaning period was also observed.
Claims
1. A lactic acid bacterium isolated from the gastrointestinal tract of a pig and selected according to the following criteria:
a) adhesion to pig gastrointestinal epithelial tissue after incubation of bacteria with pig epithelial cells in a ratio of 100:1 in phosphate buffered saline at 37°C for 30 minutes,
b) production of lactic acid as determined by
i) growth in MRS (Oxoid CM 359) medium, pH 6.2, for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction to at least 4.0, or
ii) growth in 9.5% reconstituted skimmilk, pH 6.3-6.4, for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction to at least 5.2, or
iii) growth in modified MRS medium without glucose, pH 6.2, containing equal amounts of maltose and soluble starch for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction to at least 4.5, or
iv) defined as the production of at least 10 g/l of lactic acid (D- and L-forms) when grown in MRS medium, pH 6.2, for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2,
c) bile tolerance as determined by growth in MRS medium, pH 6.2, supplemented with 0.9% bile for up to 48 hours at 37°C in an atmosphere containing 10% CO2 in H2, giving rise to a pH reduction comparable to the one defined in b) (i)-(iii),
d) acid tolerance as determined by a reduction in the number of colony-forming units/ml after incubation for 1 hour at 40°C and a pH of 2.5 not exceeding 3.2 log units, preferably less than 1 log unit, e) a generation time of about 65 minutes, preferably 30-50 minutes, when grown in MRS medium at 40°C under anaerobic conditions,
or a functionally equivalent mutant thereof.
2. A bacterium according to claim 1, which adheres to pig gastrointestinal epithelial tissue in a number of at least 4, preferably at least 16, most preferably at least 50, bacteria per epithelial cell.
3. A bacterium according to claim 1 , which is able to produce an antimicrobial agent such as hydrogen peroxide.
4. A bacterium according to claim 1, wherein the strain is selected from the group consisting of: L. acidophilus/L. gasseri isolated from the duodenum of a suckling pig; L . salivarius subsp. salivarius isolated from the jejunum of a weaning pig; L. acidophilus/L. gasseri isolated from the ileum of a weaning pig; L. crispatus isolated from the jejunum of a suckling pig; and L . salivarius subsp. salivarius isolated from the pars oesophagea of a suckling pig.
5. A bacterium according to claim 4 which is selected from the group consisting of:
L . acidophilus/L. gasseri SS28 DSM 4324
L. salivarius subsp. salivarius SS129 DSM 4325 L. acidophilus/L . gasseri SS131 DSM 4326
L. crispatus SS151 DSM 4327
L . salivarius subsp. salivarius SS258 DSM 4328
6. A bacterium according to claim 5, which is L . salivarius subsp. salivarius SS129, DSM 4325, or L. salivarius subsp. salivarius SS258, DSM 4328.
7. A liquid or frozen concentrate comprising a lactic acid bacterium according to any of claims 1-6.
8. A concentrate according to claim 7, which comprises 1×104-1×1012 viable colony-forming units/ml.
9. A concentrate according to claim 7 , which comprises a mixture of two or more Lactobacillus strains according to any of claims 4-6.
10. A freeze-dried or spray-dried powder comprising a lactic acid bacterium according to any of claims 1-6.
11. A powder according to claim 10 which comprises 104-1012 viable colony-forming units/g.
12. A powder according to claim 10 which comprises a mixture of two or more Lactobacillus strains according to any of claims 4-6.
13. A fermented milk product, which comprises a lactic acid bacterium according to any of claims 1-6.
14. A fermented milk product according to claim 13, which additionally comprises L. acidophilus and/or Bifidobacterium spp.
15. A fermented milk product according to claim 13 or 14, which comprises a mixture of two or more Lactobacillus strains according to any of claims 4-6.
16. A veterinary composition for the prophylaxis or treatment of gastrointestinal tract infections in pigs caused by enteropathogenic microorganisms, the composition comprising a lactic acid bacterium according to any of claims 1-6 and an excipient or carrier.
17. A composition according to claim 16 which comprises 10 -1012 viable colony-forming units/g.
18. A composition according to claim 16 which is formulated as a powder, granulate, tablet, capsule, paste, gel, drench, mixture or suspension.
19. A composition according to claim 18, wherein the powder is the powder according to any of claims 10-12.
20. A composition according to claim 18 or 19, wherein the powder, granulate, tablet or capsule is provided with a coating which is degradable in a gastrointestinal environment.
21. A composition according to claim 20, wherein the coating is one which is soluble in the stomach or in the upper part of the small intestine.
22. A composition according to claim 18, wherein the suspension is a suspension of the powder of any of claims 10-12 in an aqueous or oily medium, such as in the drinking water of the pig, an electrolyte solution or in a reconstituted sowmilk replacer.
23. A composition according to any of claims 16-22 which comprises a mixture of two or more Lactobacillus strains according to any of claims 4-6.
24. A process of producing a lactic acid bacterium according to claim 1, the process comprising isolating and selecting a lactic acid bacterial strain in accordance with the criteria defined in claim 1, growing the so selected bacterium in a suitable medium under anaerobic conditions for a period of time sufficient to provide at least 10° viable lactic acid bacteria/ml of medium, and harvesting the resuiting bacteria from the medium.
25. Use of a lactic acid bacterium according to any of claims 1-6 for the production of a fermented milk product.
26. Use of a liquid or frozen concentrate according to any of claims 7-9 for the production of a fermented milk product.
27. Use of a freeze-dried or spray-dried powder according to .any of claims 10-12 for the production of a fermented milk product.
28. Use of a lactic acid bacterium according to any of claims 1-6 for preparing a veterinary composition for the prophylaxis or treatment of gastrointestinal tract infections in pigs caused by enteropathogenie microorganisms.
29. Use according to claim 28, wherein the pigs for which the composition is intended are suckling or weaning pigs or porkers.
30. Use according to claim 28, wherein the composition is adapted to be sprayed or sprinkled in the environment of the pigs .
31. Use according to claim 30, wherein the composition is in the form of a powder according to any of claims 10-12.
32. Use according to claim 28, wherein the composition is in the form of a suspension in an aqueous or oily medium, such as the drinking water of the pigs, an electrolyte solution or a reconstituted sowmilk replacer.
33. Use according to claim 28, wherein the composition is in a form suited for administration to a sow.
34. Use according to claim 28, wherein the composition is adapted to be mixed with the feed of weaning pigs or porkers.
35. Use according to claim 34, wherein the composition is in the-form of a powder according to any of claims 10-12.
36. Use according to any of claims 32-35, wherein the amount of lactic acid bacteria per dosage of the composition is in the range of 104-1012, preferably 106-10i0, colony-forming units.
37. A method of preventing or treating gastrointestinal infections in pigs caused by enteropathogenic microorganisms, the method comprising administering a therapeutically effective dosage of a lactic acid bacterium according to any of claims 1-6 to pigs.
38. A method according to claim 37, wherein the pigs are suckling or weaning pigs or porkers.
39. A method according to claim 37, wherein the lactic acid bacterium is administered as a powder according to any of claims 10-12, the powder being sprayed or sprinkled in the environment of the pigs.
40. A method according to claim 37, wherein the lactic acid bacteria are administered in the form of a suspension thereof in an aqueous or oily medium, such as the drinking water of the pigs, an electrolyte solution or a reconstituted sowmilk replacer.
41. A method according to claim 40, wherein the amount of lactic acid bacteria is in the range of 104-1012, preferably 106-1010, viable colony-forming units per dosage.
42. A method according to claim 41, wherein the lactic acid bacteria are administered 1-3 times a day, for a period of up to 14 days.
43. A method according to claim 37, wherein the lactic acid bacteria are administered in the form of a powder according to any of claims 10-12, the powder being admixed with the feed of the pigs.
44. A method according to claim 43, wherein the amount of lactic acid bacteria administered is in the range of 104-1012, preferably
106-1010, viable colony-forming units per dosage.
45. A method according to claim 44, wherein the lactic acid bacteria are administered 1-3 times a day, for a period of up to 14 days.
46. A method of preventing or treating gastrointestinal tract infections in pigs caused by enteropathogenic microorganisms, the method comprising administering to a gestating or lactating sow an amount of lactic acid bacteria according to any of claims 1-6 which is sufficient to provide a therapeutically effective amount of the bacteria in the environment of the sow.
47. A method according to claim 46, wherein the amount of lactic acid bacteria administered is in the range of 105-1012, preferably
107-1011, viable colony-forming units per dosage.
48. A method according to claim 47, wherein the lactic acid bacteria are administered 1-3 times a day for a period of up to 28 days.
49. A method according to any of claims 46-48, wherein the lactic acid bacteria are administered in the form of a powder according to any of claims 10-12.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK6861/87 | 1987-12-23 | ||
DK686187A DK686187D0 (en) | 1987-12-23 | 1987-12-23 | VETERINATED PREPARATION |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989005849A1 true WO1989005849A1 (en) | 1989-06-29 |
Family
ID=8149123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1988/000222 WO1989005849A1 (en) | 1987-12-23 | 1988-12-23 | Lactic acid bacteria for use in fermented milk products and veterinary compositions |
Country Status (2)
Country | Link |
---|---|
DK (1) | DK686187D0 (en) |
WO (1) | WO1989005849A1 (en) |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0577903A1 (en) * | 1992-07-06 | 1994-01-12 | Societe Des Produits Nestle S.A. | Agent antigastrite contenant lactobacillus acidophilus |
WO1995007090A1 (en) * | 1993-09-06 | 1995-03-16 | Zeneca Limited | Probiotics |
US5474932A (en) * | 1991-07-25 | 1995-12-12 | Probi Ab | Intestine colonizing strains of lactobacilli |
WO1997016198A1 (en) * | 1995-11-02 | 1997-05-09 | Chr. Hansen Biosystems A/S | Probiotically acting formulation |
WO1998035014A2 (en) * | 1997-02-11 | 1998-08-13 | Enterprise Ireland Trading As Bioresearch Ireland | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
EP0949330A2 (en) * | 1998-04-10 | 1999-10-13 | Proge Farm S.r.l. | Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures |
WO2000010582A2 (en) * | 1998-08-24 | 2000-03-02 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
JP2001002578A (en) * | 1999-06-24 | 2001-01-09 | Yasuhiro Koga | Helicobacter pylori-removing medicament |
DE19945746C1 (en) * | 1999-09-24 | 2001-04-19 | Theodor Backs Gmbh | New Lactobacillus salivarius DSM 12000, for preventing and treating digestive tract infections in ornamental birds and for use as a feed supplement |
FR2826020A1 (en) * | 2001-06-14 | 2002-12-20 | Ceva Sante Animale | Selecting strains of lactic acid bacteria, useful for controlling infections by pathogenic bacteria, based on adhesion to tissue, each other and determinants of the pathogen |
WO2002103034A1 (en) * | 2001-06-14 | 2002-12-27 | Ceva Sante Animale | Method of selecting non-pathogenic gram-positive lactic acid bacteria strains |
FR2831555A1 (en) * | 2001-10-29 | 2003-05-02 | Ceva Sante Animale | Selecting strains of lactic acid bacteria, useful for controlling infections by pathogenic bacteria, based on adhesion to tissue, each other and determinants of the pathogen |
DE19943488B4 (en) * | 1999-09-10 | 2004-10-07 | Theodor Backs Gmbh | Means for treating pigeons |
KR100585392B1 (en) * | 2002-01-24 | 2006-05-30 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus slivarius Probio-37 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus |
US7195906B2 (en) | 1999-01-15 | 2007-03-27 | Enterprise Ireland (Trading As Bioresearch Ireland) | Bifidobacterium in the treatment of inflammatory disease |
US7323166B2 (en) | 2002-06-19 | 2008-01-29 | Board Of Regents University Of Nebraska | Lactic acid bacteria cultures that inhibit food-borne pathogens |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
GB2469059A (en) * | 2009-03-31 | 2010-10-06 | Univ Plymouth | Fermented feed comprising lactic acid producing bacteria |
US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
WO2011050426A2 (en) | 2009-10-27 | 2011-05-05 | "Selur Vk Holding" Eood | New strains of lactic acid bacteria and their combinations producing probiotic preparations |
US7998473B2 (en) | 2003-12-19 | 2011-08-16 | The Procter & Gamble Company | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
GB2484126A (en) * | 2010-09-30 | 2012-04-04 | Univ Plymouth | Foodstuff fermented with lactic acid producing bacteria |
US8551473B2 (en) | 2004-09-27 | 2013-10-08 | Multigerm Uk Enterprises Ltd. | Metabolically active micro organisms and methods for their production |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
GB2501999A (en) * | 2009-03-31 | 2013-11-13 | Univ Plymouth | Fermented feed for pigs comprising Lactobacillus plantarum |
US8691303B2 (en) | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
US8809035B2 (en) | 2003-12-19 | 2014-08-19 | The Iams Company | Canine probiotic Bifidobacterium |
US8846029B2 (en) | 2005-09-28 | 2014-09-30 | Nordisk Rebalance A/S | Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
US9210945B2 (en) | 2009-07-31 | 2015-12-15 | The Iams Company | Animal food having low water activity |
US9415083B2 (en) | 2004-05-10 | 2016-08-16 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal |
US9446111B2 (en) | 2009-04-29 | 2016-09-20 | Ganeden Biotech, Inc. | Inactivated bacterial cell formulation |
US9622502B2 (en) | 2008-10-16 | 2017-04-18 | Ganeden Biotech, Inc. | Probiotic Bacillus pasta compositions |
EP3168292A1 (en) | 2015-11-06 | 2017-05-17 | Probis Sp. z o.o. | New lactobacillus plantarum strain amt14 and composition containing the strain of lactobacillus plantarum amt14 |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US10111916B2 (en) | 2003-12-05 | 2018-10-30 | Ganeden Biotech, Inc. | Compositions comprising Bacillus coagulans spores and whey |
US10166262B2 (en) | 2017-04-20 | 2019-01-01 | Ewelina Sosnowska-Turek | Strain of bacteria and composition comprising the same |
US10383342B2 (en) | 2007-08-29 | 2019-08-20 | Ganeden Biotech, Inc. | Baked goods |
CN110615695A (en) * | 2019-09-23 | 2019-12-27 | 广西农垦永新畜牧集团金光有限公司 | Harmless treatment method for dead pigs |
CN111172077A (en) * | 2020-02-14 | 2020-05-19 | 广东中科无抗养殖科技有限公司 | Microbial preparation for regulating live pig intestinal flora and preparation method thereof |
US11154077B2 (en) | 2009-07-31 | 2021-10-26 | Mars, Incorporated | Process for dusting animal food |
US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
US11304428B2 (en) | 2015-02-16 | 2022-04-19 | Mars, Incorporated | Interlocking kibble |
US11388914B2 (en) | 2015-04-28 | 2022-07-19 | Mars, Incorporated | Process of preparing a wet pet food, wet pet food produced by the process and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0033584A2 (en) * | 1980-01-11 | 1981-08-12 | Farmos-Yhtyma Oy | Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry |
EP0199535A2 (en) * | 1985-04-17 | 1986-10-29 | Sherwood L. Gorbach | Lactobacillus acidophilus strains of bacteria and compositions thereof |
EP0203586A2 (en) * | 1985-05-29 | 1986-12-03 | Pioneer Hi-Bred International | A composition for treating gastrointestinal disease in animals |
EP0271364A2 (en) * | 1986-12-12 | 1988-06-15 | Biorem C.C. | Preparation suitable for treating enteric disorders |
-
1987
- 1987-12-23 DK DK686187A patent/DK686187D0/en not_active Application Discontinuation
-
1988
- 1988-12-23 WO PCT/DK1988/000222 patent/WO1989005849A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0033584A2 (en) * | 1980-01-11 | 1981-08-12 | Farmos-Yhtyma Oy | Process for the production of a bacterial preparation for the prophylaxis of intestinal disturbances in poultry |
EP0199535A2 (en) * | 1985-04-17 | 1986-10-29 | Sherwood L. Gorbach | Lactobacillus acidophilus strains of bacteria and compositions thereof |
EP0203586A2 (en) * | 1985-05-29 | 1986-12-03 | Pioneer Hi-Bred International | A composition for treating gastrointestinal disease in animals |
EP0271364A2 (en) * | 1986-12-12 | 1988-06-15 | Biorem C.C. | Preparation suitable for treating enteric disorders |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF APPLIED BACTERIOLOGY, 1-39, 1980, Vol. 48, BARROW et al., "The Attachment of Bacteria to the Gastric Epithelium of the Pig and its Importance in the Microecology of the Intestine", p. 147-154, see p. 150, line 33-40. * |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474932A (en) * | 1991-07-25 | 1995-12-12 | Probi Ab | Intestine colonizing strains of lactobacilli |
EP0577903A1 (en) * | 1992-07-06 | 1994-01-12 | Societe Des Produits Nestle S.A. | Agent antigastrite contenant lactobacillus acidophilus |
US5578302A (en) * | 1992-07-06 | 1996-11-26 | Nestec S.A. | Treatment of stomach ulcers |
WO1995007090A1 (en) * | 1993-09-06 | 1995-03-16 | Zeneca Limited | Probiotics |
WO1997016198A1 (en) * | 1995-11-02 | 1997-05-09 | Chr. Hansen Biosystems A/S | Probiotically acting formulation |
WO1998035014A3 (en) * | 1997-02-11 | 1998-11-19 | Forbairt Trading As Bioresearc | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
WO1998035014A2 (en) * | 1997-02-11 | 1998-08-13 | Enterprise Ireland Trading As Bioresearch Ireland | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
JP4743925B2 (en) * | 1997-02-11 | 2011-08-10 | エンタープライズ アイルランド トレーディング アズ バイオリサーチ アイルランド | Bacteria useful for living organisms derived from Lactobacillus salivarius and antibacterial agents obtained therefrom |
JP2002514068A (en) * | 1997-02-11 | 2002-05-14 | エンタープライズ アイルランド トレーディング アズ バイオリサーチ アイルランド | Bacterial strains derived from Lactobacillus salivarius useful for living organisms and antibacterial agents obtained therefrom |
AU748744B2 (en) * | 1997-02-11 | 2002-06-13 | Enterprise Ireland Trading As Bioresearch Ireland | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
US7186545B2 (en) | 1997-02-11 | 2007-03-06 | Enterprise Ireland | Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
EP0949330A3 (en) * | 1998-04-10 | 2003-05-28 | Proge Farm S.r.l. | Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures |
EP0949330A2 (en) * | 1998-04-10 | 1999-10-13 | Proge Farm S.r.l. | Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures |
EP1894996A1 (en) * | 1998-04-10 | 2008-03-05 | Proge Farm S.r.l. | Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures |
US8697055B2 (en) | 1998-08-24 | 2014-04-15 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria |
US8097247B2 (en) | 1998-08-24 | 2012-01-17 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
US8187590B2 (en) | 1998-08-24 | 2012-05-29 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
WO2000010582A2 (en) * | 1998-08-24 | 2000-03-02 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
US7807151B2 (en) | 1998-08-24 | 2010-10-05 | Ganeden Biotech, Incorporated | Probiotic, lactic acid-producing bacteria and uses thereof |
JP2002523372A (en) * | 1998-08-24 | 2002-07-30 | ガネデン バイオテック, インコーポレイテッド | Symbiotic lactic acid producing bacteria and uses thereof |
WO2000010582A3 (en) * | 1998-08-24 | 2000-07-13 | Ganeden Biotech Inc | Probiotic, lactic acid-producing bacteria and uses thereof |
US7708988B2 (en) | 1998-08-24 | 2010-05-04 | Ganeden Biotech, Incorporated | Probiotic, lactic acid-producing bacteria and uses thereof |
US7195906B2 (en) | 1999-01-15 | 2007-03-27 | Enterprise Ireland (Trading As Bioresearch Ireland) | Bifidobacterium in the treatment of inflammatory disease |
JP4509250B2 (en) * | 1999-06-24 | 2010-07-21 | 明治乳業株式会社 | Helicobacter pylori sanitizing medicine |
JP2001002578A (en) * | 1999-06-24 | 2001-01-09 | Yasuhiro Koga | Helicobacter pylori-removing medicament |
DE19943488B4 (en) * | 1999-09-10 | 2004-10-07 | Theodor Backs Gmbh | Means for treating pigeons |
DE19945746C1 (en) * | 1999-09-24 | 2001-04-19 | Theodor Backs Gmbh | New Lactobacillus salivarius DSM 12000, for preventing and treating digestive tract infections in ornamental birds and for use as a feed supplement |
FR2826020A1 (en) * | 2001-06-14 | 2002-12-20 | Ceva Sante Animale | Selecting strains of lactic acid bacteria, useful for controlling infections by pathogenic bacteria, based on adhesion to tissue, each other and determinants of the pathogen |
WO2002103034A1 (en) * | 2001-06-14 | 2002-12-27 | Ceva Sante Animale | Method of selecting non-pathogenic gram-positive lactic acid bacteria strains |
FR2831555A1 (en) * | 2001-10-29 | 2003-05-02 | Ceva Sante Animale | Selecting strains of lactic acid bacteria, useful for controlling infections by pathogenic bacteria, based on adhesion to tissue, each other and determinants of the pathogen |
KR100585392B1 (en) * | 2002-01-24 | 2006-05-30 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus slivarius Probio-37 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus |
US7323166B2 (en) | 2002-06-19 | 2008-01-29 | Board Of Regents University Of Nebraska | Lactic acid bacteria cultures that inhibit food-borne pathogens |
US10111916B2 (en) | 2003-12-05 | 2018-10-30 | Ganeden Biotech, Inc. | Compositions comprising Bacillus coagulans spores and whey |
US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
US9580680B2 (en) | 2003-12-19 | 2017-02-28 | Mars, Incorporated | Canine probiotic bifidobacterium pseudolongum |
US8900568B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
US8900569B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
US9821015B2 (en) | 2003-12-19 | 2017-11-21 | Mars, Incorporated | Methods of use of probiotic bifidobacteria for companion animals |
US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US7998473B2 (en) | 2003-12-19 | 2011-08-16 | The Procter & Gamble Company | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US8840880B2 (en) | 2003-12-19 | 2014-09-23 | The Iams Company | Canine probiotic bifidobacteria globosum |
US8809035B2 (en) | 2003-12-19 | 2014-08-19 | The Iams Company | Canine probiotic Bifidobacterium |
US8802158B2 (en) | 2003-12-19 | 2014-08-12 | The Iams Company | Methods of use of probiotic Lactobacilli for companion animals |
US9415083B2 (en) | 2004-05-10 | 2016-08-16 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal |
US8551473B2 (en) | 2004-09-27 | 2013-10-08 | Multigerm Uk Enterprises Ltd. | Metabolically active micro organisms and methods for their production |
US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
US9404162B2 (en) | 2005-05-31 | 2016-08-02 | Mars, Incorporated | Feline probiotic bifidobacteria and methods |
US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
US9427000B2 (en) | 2005-05-31 | 2016-08-30 | Mars, Incorporated | Feline probiotic lactobacilli composition and methods |
US8900570B2 (en) | 2005-09-28 | 2014-12-02 | Nordisk Rebalance A/S | Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors |
US9205114B2 (en) | 2005-09-28 | 2015-12-08 | Nordisk Rebalance A/S | Probiotic fermented cereal compositions and methods for treatment of gastrointestinal diseases caused by pro-inflammatory bacteria |
US8846029B2 (en) | 2005-09-28 | 2014-09-30 | Nordisk Rebalance A/S | Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors |
US10286026B2 (en) | 2005-09-28 | 2019-05-14 | Nordic Rebalance A/S | Probiotic fermented cereal compositions and methods for treatment of gastrointestinal diseases caused by pro-inflammatory bacteria |
US10383342B2 (en) | 2007-08-29 | 2019-08-20 | Ganeden Biotech, Inc. | Baked goods |
US10709156B2 (en) | 2008-07-07 | 2020-07-14 | Mars, Incorporated | Pet supplement and methods of making |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US9622502B2 (en) | 2008-10-16 | 2017-04-18 | Ganeden Biotech, Inc. | Probiotic Bacillus pasta compositions |
US11419355B2 (en) | 2008-10-16 | 2022-08-23 | Ganeden Biotech, Inc. | Probiotic grain-based compositions |
US10321704B2 (en) | 2008-10-16 | 2019-06-18 | Ganeden Biotech, Inc. | Probiotic grain-based compositions |
CN102480995A (en) * | 2009-03-31 | 2012-05-30 | 普利茅斯大学 | Components for animal feed and use thereof |
CN102480995B (en) * | 2009-03-31 | 2014-06-04 | 普利茅斯大学 | Components for animal feed and use thereof |
GB2501999A (en) * | 2009-03-31 | 2013-11-13 | Univ Plymouth | Fermented feed for pigs comprising Lactobacillus plantarum |
GB2469059B (en) * | 2009-03-31 | 2014-01-08 | Univ Plymouth | Components for animal feed and use thereof |
WO2010112861A1 (en) * | 2009-03-31 | 2010-10-07 | University Of Plymouth | Components for animal feed and use thereof |
GB2469059A (en) * | 2009-03-31 | 2010-10-06 | Univ Plymouth | Fermented feed comprising lactic acid producing bacteria |
US9446111B2 (en) | 2009-04-29 | 2016-09-20 | Ganeden Biotech, Inc. | Inactivated bacterial cell formulation |
US9757442B2 (en) | 2009-04-29 | 2017-09-12 | Ganeden Biotech, Inc. | Inactivated bacterial cell formulation |
US9210945B2 (en) | 2009-07-31 | 2015-12-15 | The Iams Company | Animal food having low water activity |
US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
US11154077B2 (en) | 2009-07-31 | 2021-10-26 | Mars, Incorporated | Process for dusting animal food |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US8691303B2 (en) | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
WO2011050426A2 (en) | 2009-10-27 | 2011-05-05 | "Selur Vk Holding" Eood | New strains of lactic acid bacteria and their combinations producing probiotic preparations |
EP2634269A1 (en) | 2009-10-27 | 2013-09-04 | "Selur Vk Holding" Eood | New strain of lactic acid bacteria and its combinations producing probiotic preparations |
GB2484126A (en) * | 2010-09-30 | 2012-04-04 | Univ Plymouth | Foodstuff fermented with lactic acid producing bacteria |
WO2012042223A2 (en) | 2010-09-30 | 2012-04-05 | University Of Plymouth | Fermented foodstuff |
US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
US11351206B2 (en) | 2011-03-31 | 2022-06-07 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
US11304428B2 (en) | 2015-02-16 | 2022-04-19 | Mars, Incorporated | Interlocking kibble |
US11388914B2 (en) | 2015-04-28 | 2022-07-19 | Mars, Incorporated | Process of preparing a wet pet food, wet pet food produced by the process and uses thereof |
EP3168292A1 (en) | 2015-11-06 | 2017-05-17 | Probis Sp. z o.o. | New lactobacillus plantarum strain amt14 and composition containing the strain of lactobacillus plantarum amt14 |
US10166262B2 (en) | 2017-04-20 | 2019-01-01 | Ewelina Sosnowska-Turek | Strain of bacteria and composition comprising the same |
CN110615695A (en) * | 2019-09-23 | 2019-12-27 | 广西农垦永新畜牧集团金光有限公司 | Harmless treatment method for dead pigs |
CN111172077A (en) * | 2020-02-14 | 2020-05-19 | 广东中科无抗养殖科技有限公司 | Microbial preparation for regulating live pig intestinal flora and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
DK686187D0 (en) | 1987-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1989005849A1 (en) | Lactic acid bacteria for use in fermented milk products and veterinary compositions | |
US5951977A (en) | Competitive exclusion culture for swine | |
Sissons | Potential of probiotic organisms to prevent diarrhoea and promote digestion in farm animals–a review | |
US5340577A (en) | Probiotic for control of salmonella | |
EP1005353B1 (en) | Pharmaceutical preparation comprising lactobacillus casei rhamnosus | |
EP1112692B1 (en) | Drinks and foods capable of eliminating helicobacter pylori | |
US5296221A (en) | Lactobacillus johnsonii ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations | |
EP1162987B1 (en) | Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome | |
US5308615A (en) | Probiotic for control of Salmonella | |
JP3648233B2 (en) | Feed composition | |
WO1995007090A1 (en) | Probiotics | |
CA2100774C (en) | Feed additive and method | |
RU2086248C1 (en) | Probiotic preparation for animals | |
WO2017105267A1 (en) | New probiotic starter culture for human and animal use | |
EP2633084A2 (en) | Foodstuff fermented with a lactic acid producing bacteria | |
KR20080011901A (en) | Probiotic effects of fermented mixture of prepared with milk and soymilk use to lactobacillus salivarius sp. salivarius df20 on piglets | |
Newman et al. | Microbial feed additives for pre‐ruminants | |
JP3052208B2 (en) | Lactobacillus acidophilus F-133, lactic acid bacteria preparation using the same and method for producing the same | |
KR100206454B1 (en) | A novel lactobacillus sp ds-12 and use as a probiotic for fish | |
FI112374B (en) | Method for the administration of direct-fed microorganisms to poultry in ovo | |
Dutta et al. | Mechanism of action and health benefits of probiotics. | |
FOODS | 3rd INTERNATIONAL PROBIOTIC CONFERENCE–SPEAKER’S ABSTRACTS | |
Monsan et al. | 11 Oligosaccharide feed additives | |
Fuller et al. | Bacterial interactions in the gut |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): DK FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |